

Table 1
Subject characteristics.

	Patients with schizophrenia			Statistical test results	Healthy controls			Statistical test results
	Asp/Asp	Asp/Ala	Ala/Ala		Asp/Asp	Asp/Ala	Ala/Ala	
All subjects								
Gender (males/females)	15/17	26/23	14/9	$\chi^2 = 1.1, p = 0.59$	14/24	31/29	11/3	$\chi^2 = 7.3, p = 0.03$
Age (years)	38.8 ± 13.9	40.8 ± 12.3	35.3 ± 8.5	$F = 1.64, p = 0.20$	41.0 ± 13.0	38.4 ± 13.1	39.2 ± 11.2	$F = 0.48, p = 0.62$
Duration of illness (years)	16.7 ± 11.0	17.7 ± 10.7	15.4 ± 8.8	$F = 0.39, p = 0.68$				
Duration of treatment (years)	13.0 ± 8.6	15.1 ± 10.1	12.3 ± 7.8	$F = 0.91, p = 0.41$				
CP equivalent dose	852 ± 685	993 ± 883	1030 ± 667	$F = 0.44, p = 0.65$				
Subjects selected for the measurement of sIL-6R levels								
Gender (males/females)	9/9	9/9	8/9	$\chi^2 = 0.04, p = 0.98$	6/12	7/10	11/3	$\chi^2 = 7.1, p = 0.03$
Age (years)	41.2 ± 10.2	40.6 ± 12.1	36.1 ± 7.6	$F = 1.28, p = 0.29$	43.5 ± 10.1	37.8 ± 13.3	39.2 ± 11.2	$F = 1.15, p = 0.32$
Duration of illness (years)	17.0 ± 7.3	18.1 ± 11.2	16.3 ± 7.7	$F = 0.17, p = 0.84$				
Duration of treatment (years)	14.8 ± 8.1	16.4 ± 10.8	12.2 ± 6.2	$F = 1.02, p = 0.37$				
CP equivalent dose	922 ± 688	1020 ± 788	1094 ± 746	$F = 0.24, p = 0.79$				

Continuous values are shown as mean ± standard deviation, CP: chlorpromazine.

sIL-6R is generated by shedding of the membrane-bound IL-6R. This process is influenced by the single nucleotide polymorphism (SNP) Asp358Ala of the IL-6R gene (rs8192284), which results in an amino acid substitution in the proteolytic cleavage site. The Ala allele of this polymorphism in healthy subjects is known to be strongly associated with higher levels of circulating sIL-6R (Galicia et al., 2004; Rafiq et al., 2007; Reich et al., 2007) and IL-6 (Jiang et al., 2010; Rafiq et al., 2007; Reich et al., 2007). Therefore, possession of the Ala allele may result in constitutively elevated IL-6 signaling.

A previous genetic association study reported a significant association of the Ala allele of the IL-6R Asp358Ala polymorphism with schizophrenia (Sun et al., 2008). It can be hypothesized that the excessive IL-6 signaling associated with Ala alleles may increase the susceptibility to schizophrenia. However, the increased IL-6 levels without significant change in sIL-6R levels in schizophrenic patients (Potvin et al., 2008) could not be explained solely by the increased Ala allele frequency in schizophrenia.

To our knowledge, the possible associations of the IL-6R Asp358Ala polymorphism with circulating sIL-6R and IL-6 levels in patients with schizophrenia have not yet been examined. Further investigation of the influence of this polymorphism in schizophrenia is necessary to elucidate the roles of IL-6 and sIL-6R in this disorder. Thus, we compared the plasma levels of IL-6 and sIL-6R between patients with schizophrenia and healthy controls for each genotype of the Asp358Ala polymorphism.

2. Materials and methods

2.1. Subjects

Asp358Ala genotyping and plasma IL-6 level measurements were performed in 104 patients with schizophrenia (55 men and 49 women; mean age ± standard deviation: 39.0 ± 12.2 years), and 112 healthy controls (56 men and 56 women; age: 39.4 ± 12.8 years), frequency-matched for sex and age. Of these participants, 53 schizophrenic patients (26 men and 27 women; age: 39.4 ± 10.2 years) and 49 controls (24 men and 25 women; age: 40.3 ± 11.6 years), matched for the number of cases and controls for each

genotype, were selected for the measurement of plasma sIL-6R levels. All subjects were biologically unrelated Japanese individuals and were recruited from the outpatient clinic of the National Center of Neurology and Psychiatry Hospital, Tokyo, Japan or through advertisements in free local information magazines and by our website announcement. Consensus diagnosis by at least 2 psychiatrists was made for each patient according to the Diagnostic and Statistical Manual of Mental Disorders, 4th edition criteria (American Psychiatric Association, 1994), on the basis of unstructured interviews and information from medical records. All patients were under treatment with antipsychotic medication, of which 25 were receiving inpatient treatment. The average chlorpromazine equivalent dose converted from daily doses of antipsychotics using published guidelines (American Psychiatric Association, 1997; Inagaki et al., 1999) was 957.0 ± 776.7 mg/day (typical antipsychotics, 528.8 ± 747.7 mg/day; atypical antipsychotics, 428.2 ± 458.0 mg/day). The mean age at onset was 21.9 ± 7.1 years, and the mean durations of illness and antipsychotic treatment were 16.9 ± 10.3 and 13.8 ± 9.2 years, respectively. The controls were healthy volunteers with no current or past histories of psychiatric treatment and were screened using the Japanese version of the Mini International Neuropsychiatric Interview (Otsubo et al., 2005; Sheehan et al., 1998) by a research psychiatrist to eliminate the possibility of any axis I psychiatric disorders. Participants were excluded if they had prior medical histories of central nervous system diseases or severe head injury or if they met the criteria for substance abuse or dependence or mental retardation. The self-reports indicated that none of the participants suffered from any inflammatory or infectious diseases at the time of assessment. The study protocol was approved by the ethics committee at the National Center of Neurology and Psychiatry, Japan. After describing the study, written informed consent was obtained from every subject.

2.2. Genotyping

Genomic DNA was prepared from venous blood according to standard procedures. The Asp358Ala polymorphism was genotyped using the TaqMan 5'-exonuclease allelic discrimination assay.

Table 2
Distribution of the Asp358Ala variants.

	Genotype count (frequency)					Allele count (frequency)				HWE			
	N	Asp/Asp	Asp/Ala	Ala/Ala	χ^2 (df = 2)	P value	N	Asp	Ala	χ^2 (df = 1)	P value	χ^2 (df = 1)	P value
Patients	104	32 (0.31)	49 (0.47)	23 (0.22)	3.52	0.17	208	113 (0.54)	95 (0.46)	1.80	0.18	1.69	0.19
Controls	112	38 (0.34)	60 (0.54)	14 (0.13)			224	136 (0.61)	88 (0.39)			0.27	0.61

HWE: Hardy–Weinberg equilibrium.

Table 3
IL-6 and sIL-6R levels in patients with schizophrenia and healthy controls.

		Patients with schizophrenia			Healthy controls			Mann–Whitney's test
		N	Mean	S.D.	N	Mean	S.D.	
IL-6 (pg/ml)	Both genders	104	1.80	0.99	112	1.43	0.56	$U = 4296, P = 0.00087$
	Males	55	1.87	1.00	56	1.53	0.64	$U = 1261, P = 0.10$
	Females	49	1.73	0.99	56	1.33	0.44	$U = 879, P = 0.0015$
sIL-6R (pg/ml)	Both genders	53	453	127	49	463	136	$U = 1273, P = 0.86$
	Males	26	461	124	24	511	137	$U = 244, P = 0.18$
	Females	27	446	132	25	416	120	$U = 279, P = 0.28$

IL-6: interleukin-6; sIL-6R: soluble interleukin-6 receptor, S.D.: standard deviation.

The thermal cycling conditions for polymerase chain reaction were as follows: 1 cycle at 95 °C for 10 min followed by 50 cycles of 92 °C for 15 s and 60 °C for 1 min. The allele-specific fluorescence was measured with ABI PRISM 7900 Sequence Detection Systems (Applied Biosystems, Foster City, CA). Ambiguous genotype data were not included in the analysis.

2.3. Laboratory methods

Plasma samples were collected between 1100 and 1200 h in tubes containing ethylenediaminetetraacetic acid. The samples were stored at –80 °C until they were assayed. Plasma levels of IL-6 were determined by the BD™ Cytometric Bead Array system using the BD FACSCanto II system (BD Biosciences, San Jose, CA), according to the manufacturer's instructions. Data analysis was performed using the FCAP Array software (BD Biosciences). Plasma levels of sIL-6R were measured using a commercially available immunoassay kit (Quantikine; R&D Systems, Inc., Minneapolis, MN), according to the manufacturer's instructions.

2.4. Statistical analysis

Deviations of genotype distributions from Hardy–Weinberg equilibrium (HWE) were assessed using the χ^2 test for goodness of fit. Genotype and allele distributions were compared between patients and controls by using the χ^2 test for independence. Comparison of continuous variables was analyzed using one-way analysis of variance or Mann–Whitney's test, according to the data distribution. Non-continuous variables were analyzed using χ^2 tests. To determine the possible interaction effects between diagnosis and Asp358Ala genotype, two-way factorial analysis of covariance (ANCOVA) was performed with the transformed plasma levels as the dependent variable, diagnosis and genotype as independent variables, and sex and age as covariates. Because the plasma IL-6 and sIL-6R levels were not normally distributed, the aligned rank transformation method was used to transform the data prior to conducting ANCOVA (Wobbrock et al., 2011). Post-hoc

comparisons between genotypes were Bonferroni-corrected for multiple comparisons. Correlations between continuous values were assessed using Spearman's correlation coefficient. Statistical analyses were performed using the Statistical Package for the Social Sciences version 11.0 (SPSS Japan, Tokyo, Japan). All statistical tests were two-tailed, and $P < 0.05$ indicated statistical significance.

3. Results

The subject characteristics for each genotype of the IL-6R Asp358Ala polymorphism are shown in Table 1. Table 2 shows the genotype and allele frequencies of the Asp358Ala polymorphism in the patients and controls. The genotype distribution did not significantly deviate from HWE in the patient or control group. No significant differences were found in the Asp358Ala genotype or allele distribution between the patients and controls. However, analysis under the recessive genetic model suggested a trend of higher frequencies of the Ala/Ala genotype in schizophrenic patients ($\chi^2 = 3.51, P = 0.061$). Table 3 shows the overall mean plasma IL-6 and sIL-6R levels. IL-6 levels were significantly higher in patients with schizophrenia compared to those in the controls. In contrast, no significant difference in sIL-6R levels was observed between patients and controls. The associations of IL-6 and sIL-6R levels with clinical characteristics are shown in Table 4. The IL-6 and sIL-6R levels were significantly higher in healthy men than in healthy women. Age exhibited significant correlations with IL-6 levels in the patients and controls. The duration of illness and treatment also exhibited significant correlations with IL-6 levels in the patients; however, after controlling for age, these correlations with IL-6 levels were not significant any more (duration of illness: $\rho = 0.10, P = 0.30$; duration of treatment: $\rho = 0.16, P = 0.11$). The chlorpromazine equivalent dose was not significantly correlated with IL-6 or sIL-6R levels.

The plasma IL-6 and sIL-6R levels of patients with schizophrenia and healthy controls in each genotype of the Asp358Ala polymorphism are shown in Fig. 1. Table 5 presents the results of the two-way ANCOVA performed with the transformed plasma levels

Table 4
Associations of IL-6 and sIL-6R levels with clinical characteristics.

	Statistical test results			
	Patients with schizophrenia		Healthy controls	
	IL-6 (N = 104)	sIL-6R (N = 53)	IL-6 (N = 112)	sIL-6R (N = 49)
Gender (males/females)	$U = 1264, p = 0.59$	$U = 328, p = 0.68$	$U = 1170, p = 0.020^a$	$U = 169, p = 0.009^a$
Age (years)	$\rho = 0.32, p < 0.0009^b$	$\rho = -0.19, p = 0.18$	$\rho = 0.32, p = 0.0006^b$	$\rho = -0.15, p = 0.32$
Duration of illness (years)	$\rho = 0.33, p = 0.0008^b$	$\rho = 0.029, p = 0.84$		
Duration of treatment (years)	$\rho = 0.33, p = 0.0007^b$	$\rho = 0.012, p = 0.94$		
CP equivalent dose	$\rho = 0.042, p = 0.67$	$\rho = 0.039, p = 0.78$		

IL-6: interleukin-6; sIL-6R: soluble interleukin-6 receptor.

Age, duration of illness, and duration of treatment were significantly correlated with IL-6 levels in patients with schizophrenia (Spearman's rank correlation test).

^a The IL-6 and sIL-6R levels were significantly higher in healthy males compared to healthy females (Mann–Whitney's test).

^b Age was significantly correlated with IL-6 levels in healthy controls (Spearman's rank correlation test).




Fig. 1. The mean plasma levels of IL-6 and sIL-6R in patients with schizophrenia and controls are shown for each genotype of the IL-6R Asp358Ala. Error bars indicate the standard error of the means. †Significant difference between schizophrenia and controls (Mann–Whitney's test, $p < 0.05$); n.s.: no significant difference; IL-6: interleukin-6; sIL-6R: soluble interleukin-6 receptor.

as the dependent variable, diagnosis and the genotype as independent variables, and sex and age as covariates. Because the recessive genetic model suggested a trend of higher frequencies of the Ala/Ala genotype in schizophrenic patients, we used the recessive model as well as the co-dominant model in the ANCOVA analysis. Regarding IL-6 levels, two-way ANCOVA revealed significant effect of diagnosis and of Asp358Ala genotype with no significant diagnosis \times genotype interaction. In the co-dominant model, Bonferroni's post hoc tests revealed a significant difference between Asp/Ala and Ala/Ala genotypes and a trend toward significance between Asp/Asp and Ala/Ala genotypes. Regarding sIL-6R levels, two-way ANCOVA demonstrated a significant effect of the genotype but not of the diagnosis and no significant diagnosis \times genotype interaction. Post hoc tests revealed significant differences across genotypes.

4. Discussion

The results show that the Ala allele of the IL-6R Asp358Ala polymorphism is associated with higher plasma levels of IL-6 and

sIL-6R in both patients with schizophrenia and healthy controls. The overall IL-6 levels were elevated in schizophrenic patients with no significant change in sIL-6R levels. Consistent with our findings, previous studies of healthy subjects also showed that higher levels of sIL-6R and IL-6 levels were associated with the Ala allele of Asp358Ala (Galicia et al., 2004; Rafiq et al., 2007; Reich et al., 2007). A two-way factorial ANCOVA revealed no significant diagnosis \times genotype interaction for IL-6 and sIL-6R levels. Taken together, our findings suggest that the IL-6 levels of schizophrenic patients are elevated compared to those of their healthy counterparts irrespective of the Asp358Ala genotype and that the increase in IL-6 levels without alterations in sIL-6R levels results in excessive IL-6 signaling in schizophrenic patients.

Consistent with the previous finding that the Ala allele was associated with susceptibility to schizophrenia (Sun et al., 2008), our results indicated a trend of higher frequencies of the Ala/Ala genotype in schizophrenic patients. Taken together with the finding that the Ala allele was associated with higher IL-6 and sIL-6R levels, our results lend support to the evidence that excessive IL-6 signaling could cause neurodevelopmental abnormalities

Table 5
The results of the two-way ANCOVA.

	Diagnosis		Genotypes of Asp358Ala		Interaction		Post hoc tests between genotypes					
	F value	P value	F value	P value	F value	P value	Asp/Asp vs Asp/Ala		Asp/Ala vs Ala/Ala		Ala/Ala vs Asp/Asp	
							F value	P value ^a	F value	P value ^a	F value	P value ^a
Co-dominant model (Asp/Asp vs Asp/Ala vs Ala/Ala)												
Plasma IL-6 levels	7.03	0.01	3.96	0.02	1.07	0.35	0.74	1.0	6.59	0.03	5.14	0.08
Plasma sIL-6R levels	0.36	0.55	105	<0.0001	0.25	0.78	65.4	<0.0001	40.4	<0.0001	237	<0.0001
Recessive model (Asp/Asp + Asp/Ala vs Ala/Ala)												
Plasma IL-6 levels	6.74	0.010	8.11	0.0048	1.00	0.32						
Plasma sIL-6R levels	0.03	0.86	82.5	<0.0001	0.63	0.43						

ANCOVA was performed with the transformed plasma levels as the dependent variable, the diagnosis and the genotype as independent variables, and sex and age as covariates.

ANCOVA: analysis of covariance; IL-6: interleukin-6; sIL-6R: soluble interleukin-6 receptor.

^a Bonferroni-corrected P values.

associated with schizophrenia (Gilmore et al., 2004; Marx et al., 2001). To conclude the possible genetic association between the Asp358Ala polymorphism and schizophrenia, further studies in a larger sample size are required.

Recent studies have shown that IL-6 signaling functions as a risk factor for the development of schizophrenia. Behrens et al. (2008) reported that IL-6 production by neurons induces NAPDH oxidase and subsequently leads to the degeneration of parvalbumin, the dysfunction of which is considered one of the key features in the brain pathology of schizophrenia (Lewis et al., 2005). In an animal study, injection of IL-6 alone into mothers was sufficient to cause schizophrenia-like behavioral abnormalities in the offspring, whereas anti-IL-6 antibody blocked the development of such abnormalities (Smith et al., 2007).

The two-way ANCOVA revealed that IL-6 levels in schizophrenic patients were elevated compared to those in controls with no significant diagnosis \times genotype interaction, suggesting that some schizophrenia-related factors other than the Asp358Ala polymorphism are associated with elevated IL-6 levels. Conversely, similar sIL-6R levels between schizophrenic patients and the controls suggest that sIL-6R levels are mainly predetermined by the IL-6R Asp358Ala polymorphism and are unrelated to the disease status.

Because IL-6 levels are affected by a number of environmental and genetic factors, various conditions may be attributed to increased IL-6 levels in schizophrenic patients. For example, acute mental stress could induce a significant increase in plasma IL-6 levels (von Kanel et al., 2006). Therefore, stressful life events triggering the exacerbation of psychotic symptoms, as well as psychological stress caused by the onset of the disease, may have contributed in the elevation of IL-6 levels. Stimulation of the peripheral immune system can result in activation of microglia in the central nervous system. According to the recent microglia hypothesis of schizophrenia (Monji et al., 2009), activated microglia release pro-inflammatory cytokines and free radicals, thereby causing neuronal degeneration, white matter abnormalities, and decreased neurogenesis associated with the pathophysiology of schizophrenia. Genetic variations other than the one examined in this study may also play a role in the regulation of IL-6 levels in schizophrenic patients. For example, a well-known functional polymorphism, $-174G/C$ of the IL-6 gene, known to affect the circulating levels of IL-6 (Bonafe et al., 2001; Fishman et al., 1998; Olivieri et al., 2002), was found to be associated with schizophrenia in a Caucasian population (Paul-Samojedny et al., 2010). Although this SNP is reported as monomorphic in the HapMap Japanese population, there may still be other unknown genetic polymorphisms attributable to higher IL-6 levels in patients with schizophrenia.

Previous studies have suggested the influence of antipsychotic treatment on the IL-6 and sIL-6R levels in schizophrenic patients. Xu et al. (1994) reported higher plasma IL-6 levels in schizophrenic patients taking antipsychotic medication than in neuroleptic-free patients. Loffler et al. (2010) reported that treatment with clozapine increased plasma IL-6 levels. In line with this, van Kammen et al. (1999) reported that exacerbation after haloperidol withdrawal resulted in decreased plasma IL-6 levels. In contrast, a larger study by Zhang et al. (2004) demonstrated no significant influence of risperidone or haloperidol on serum IL-6 levels in their schizophrenic patients. Regarding sIL-6R, one study reported a significant decrease of the serum levels after neuroleptic treatment (Muller et al., 1997). The present study obtained no evidence of association between the antipsychotic dose and the levels of IL-6 and sIL-6R, which is consistent with Zhang et al. (2004). Although the duration of antipsychotic treatment and the duration of illness correlated significantly with IL-6 levels, which is consistent with

some previous studies (Ganguli et al., 1994; Kim et al., 2000), these significant correlations appeared to reflect the influence of age, as the correlations disappeared after controlling for age. Further studies are required to draw conclusions as to the possible influence of antipsychotic medication on IL-6 and sIL-6R levels.

Some limitations must be considered when interpreting the results of this study. First, the cross-sectional design did not allow for any definitive conclusions regarding whether the increased IL-6 levels in schizophrenic patients were premorbid or the result of illness onset. Secondly, only the IL-6R Asp358Ala polymorphism was examined in the present study. Future studies should examine gene-wide tagging polymorphisms of IL-6 and IL-6R genes and their associations with the circulating levels of IL-6 and sIL-6R in schizophrenic patients. Thirdly, we did not assess inflammation markers such as C-reactive protein. As the presence or absence of inflammatory diseases was based only on self-reports, the results may have been affected by unrecognized inflammatory processes in some participants.

In conclusion, the Ala allele of the IL-6R Asp358Ala polymorphism was found to be associated with higher plasma levels of both IL-6 and sIL-6R in schizophrenic patients and controls. The overall IL-6 levels were elevated in schizophrenic patients with no significant change in sIL-6R levels, supporting the role of excessive IL-6 signaling in schizophrenia. The finding that the IL-6 levels in schizophrenic patients were elevated with no significant diagnosis \times genotype interaction suggests that some schizophrenia-related factors, other than the effects of the polymorphism, are associated with increased IL-6 levels in schizophrenic patients. In contrast, the sIL-6R levels are mainly predetermined by the polymorphism and are not influenced by the disease status.

Contributors

D.S., C.W., and H.K. designed the study and D.S. wrote the draft of the manuscript. D.S., H.H., T.T., K.H., and M.O. screened the study participants using the Mini International Neuropsychiatric Interview (M.I.N.I.). C.W. measured the IL-6 levels and D.S. measured the sIL-6R levels. D.S. performed the genotyping. D.S. and H.H. undertook the statistical analysis. H.K. supervised the data analysis and writing of the paper. M.I., K.A., T.H., and N.A. also supervised the writing of the paper and gave critical comments on the manuscript. All authors contributed to and have approved the final manuscript.

Role of funding source

This study was supported by Health and Labor Sciences Research Grants (Comprehensive Research on Disability, Health, and Welfare), Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (JSPS), the Strategic Research Program for Brain Sciences by the Ministry of Education, Culture, Sports, Science and Technology of Japan (Understanding of molecular and environmental bases for brain health), and Intramural Research Grant for Neurological and Psychiatric Disorders of NCNP (H.K.). They had no further role in study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication.

Conflict of interest


The authors report no conflicts of interest.

Acknowledgments

The authors would like to thank the participants for taking part in the study.

References

- American Psychiatric Association. DSM-IV: diagnostic and statistical manual of mental disorders. 4th ed. Washington D.C.: American Psychiatric Press; 1994.
- American Psychiatric Association. Practice guidelines for the treatment of patients with schizophrenia. Washington D.C.: American Psychiatric Press; 1997.
- Behrens MM, Ali SS, Dugan LL. Interleukin-6 mediates the increase in NADPH-oxidase in the ketamine model of schizophrenia. *Journal of Neuroscience* 2008;28:13957–66.
- Bonafe M, Olivieri F, Cavallone L, Giovagnetti S, Mayegiani F, Cardelli M, et al. A gender-dependent genetic predisposition to produce high levels of IL-6 is detrimental for longevity. *European Journal of Immunology* 2001;31:2357–61.
- Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S, Woo P. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. *Journal of Clinical Investigation* 1998;102:1369–76.
- Galicia JC, Tai H, Komatsu Y, Shimada Y, Akazawa K, Yoshie H. Polymorphisms in the IL-6 receptor (IL-6R) gene: strong evidence that serum levels of soluble IL-6R are genetically influenced. *Genes and Immunity* 2004;5:513–6.
- Ganguli R, Yang Z, Shurin G, Chengappa KN, Brar JS, Gubbi AV, Rabin BS. Serum interleukin-6 concentration in schizophrenia: elevation associated with duration of illness. *Psychiatry Research* 1994;51:1–10.
- Gilmore JH, Fredrik Jarskog L, Vadlamudi S, Lauder JM. Prenatal infection and risk for schizophrenia: IL-1beta, IL-6, and TNFalpha inhibit cortical neuron dendrite development. *Neuropsychopharmacology* 2004;29:1221–9.
- Inagaki A, Inada T, Fujii Y, Yagi G. Equivalent dose of psychotropics. Tokyo: Seiwa Shoten; 1999.
- Jiang CQ, Lam TH, Liu B, Lin JM, Yue XJ, Jin YL, et al. Interleukin-6 receptor gene polymorphism modulates interleukin-6 levels and the metabolic syndrome: GBCS-CVD. *Obesity (Silver Spring)* 2010;18:1969–74.
- Kim YK, Kim L, Lee MS. Relationships between interleukins, neurotransmitters and psychopathology in drug-free male schizophrenics. *Schizophrenia Research* 2000;44:165–75.
- Lewis DA, Hashimoto T, Volk DW. Cortical inhibitory neurons and schizophrenia. *Nature Reviews Neuroscience* 2005;6:312–24.
- Lin A, Kenis G, Bignotti S, Tura CJ, De Jong R, Bosmans E, et al. The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6. *Schizophrenia Research* 1998;32:9–15.
- Loffler S, Klimke A, Kronenwett R, Kobbe G, Haas R, Fehsel K. Clozapine mobilizes CD34(+) hematopoietic stem and progenitor cells and increases plasma concentration of interleukin 6 in patients with schizophrenia. *Journal of Clinical Psychopharmacology* 2010;30:591–5.
- Maes M, Meltzer HY, Bosmans E. Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine. *Acta Psychiatrica Scandinavica* 1994;89:346–51.
- Maes M, Bosmans E, Calabrese J, Smith R, Meltzer HY. Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. *Psychiatry Research* 1995;29:141–52.
- Maes M, Bosmans E, De Jongh R, Kenis G, Vandoolaeghe E, Neels H. Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. *Cytokine* 1997;9:853–8.
- Marx CE, Jarskog LF, Lauder JM, Lieberman JA, Gilmore JH. Cytokine effects on cortical neuron MAP-2 immunoreactivity: implications for schizophrenia. *Biological Psychiatry* 2001;50:743–9.
- Monji A, Kato T, Kanba S. Cytokines and schizophrenia: microglia hypothesis of schizophrenia. *Psychiatry and Clinical Neurosciences* 2009;63:257–65.
- Muller N, Empl M, Riedel M, Schwarz M, Ackenheil M. Neuroleptic treatment increases soluble IL-2 receptors and decreases soluble IL-6 receptors in schizophrenia. *European Archives of Psychiatry and Clinical Neuroscience* 1997;247:308–13.
- O'Brien SM, Scully P, Dinan TG. Increased tumor necrosis factor-alpha concentrations with interleukin-4 concentrations in exacerbations of schizophrenia. *Psychiatry Research* 2008;160:256–62.
- Olivieri F, Bonafe M, Cavallone L, Giovagnetti S, Marchegiani F, Cardelli M, et al. The -174C/G locus affects in vitro/in vivo IL-6 production during aging. *Experimental Gerontology* 2002;37:309–14.
- Otsubo T, Tanaka K, Koda R, Shinoda J, Sano N, Tanaka S, et al. Reliability and validity of Japanese version of the mini-international neuropsychiatric interview. *Psychiatry and Clinical Neurosciences* 2005;59:517–26.
- Pae CU, Yoon CH, Kim TS, Kim JJ, Park SH, Lee CU, et al. Antipsychotic treatment may alter T-helper (TH) 2 arm cytokines. *Journal of Neuroscience* 2006;6:666–71.
- Paul-Samojedny M, Kowalczyk M, Suchanek R, Owczarek A, Fila-Danilow A, Szczygiel A, Kowalski J. Functional polymorphism in the interleukin-6 and interleukin-10 genes in patients with paranoid schizophrenia – a case-control study. *Journal of Molecular Neuroscience* 2010;42:112–9.
- Potvin S, Stip E, Sepehry AA, Gendron A, Bah R, Kouassi E. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. *Biological Psychiatry* 2008;63:801–8.
- Rafiq S, Fraying TM, Murray A, Hurst A, Stevens K, Weedon MN, et al. A common variant of the interleukin 6 receptor (IL-6r) gene increases IL-6r and IL-6 levels, without other inflammatory effects. *PLoS ONE* 2007;8:552–9.
- Reich D, Patterson N, Ramesh V, De Jager PL, McDonald GJ, Tandon A, et al. Admixture mapping of an allele affecting interleukin 6 soluble receptor and interleukin 6 levels. *American Journal of Human Genetics* 2007;80:716–26.
- Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. *Journal of Clinical Psychiatry* 1998;59(Suppl. 20):22–33 [quiz 34–57].
- Smith SE, Li J, Garbett K, Mirnics K, Patterson PH. Maternal immune activation alters fetal brain development through interleukin-6. *International Immunopharmacology* 2007;27:10695–702.
- Sun S, Wang F, Wei J, Cao LY, Qi LY, Xiu MH, et al. Association between interleukin-6 receptor polymorphism and patients with schizophrenia. *Schizophrenia Research* 2008;102:346–7.
- van Kammen DP, McAllister-Sistilli CG, Kelley ME, Gurklis JA, Yao JK. Elevated interleukin-6 in schizophrenia. *Psychiatry Research* 1999;87:129–36.
- von Kanel R, Kudielka BM, Preckel D, Hanebuth D, Fischer JE. Delayed response and lack of habituation in plasma interleukin-6 to acute mental stress in men. *Brain Behavior and Immunity* 2006;20:40–8.
- Watanabe Y, Someya T, Nawa H. Cytokine hypothesis of schizophrenia pathogenesis: evidence from human studies and animal models. *Psychiatry and Clinical Neurosciences* 2010;64:217–30.
- Wobbrock JO, Findlater L, Gergle D, Higgins JJ. The aligned rank transform for nonparametric factorial analyses using only ANOVA procedures. In: Proceedings of CHI 2011 conference on human factors in computing systems, vol. 1; 2011. 143–146.
- Xu HM, Wei J, Hemmings GP. Changes of plasma concentrations of interleukin-1 alpha and interleukin-6 with neuroleptic treatment for schizophrenia. *British Journal of Psychiatry* 1994;164:251–3.
- Zhang XY, Zhou DF, Cao LY, Zhang PY, Wu GY, Shen YC. Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia. *Journal of Clinical Psychiatry* 2004;65:940–7.



Relationships between season of birth, schizotypy, temperament, character and neurocognition in a non-clinical population

Hiroaki Hori*, Toshiya Teraishi, Daimei Sasayama, Junko Matsuo, Yumiko Kawamoto, Yukiko Kinoshita, Hiroshi Kunugi

Department of Mental Disorder Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, 4-1-1, Ogawahigashi, Kodaira, Tokyo, 187-8502, Japan

ARTICLE INFO

Article history:

Received 20 December 2010
Received in revised form 13 July 2011
Accepted 16 July 2011

Keywords:

Schizotypal personality
Schizophrenia
Season of birth
Cognitive function
Temperament
Character

ABSTRACT

While schizophrenia has been associated with a slight excess of winter/early spring birth, it is unclear whether there is such an association in relation to schizotypal personality traits. Season of birth has also been reported to relate to temperament and character personality dimensions and cognitive functioning. Moreover, non-clinical schizotypy has been shown to be associated with mild cognitive impairment, although its precise nature is yet to be elucidated. Here we examined the relationships between season of birth, schizotypal traits, temperament and character, and cognitive function. Four hundred and fifty-one healthy adults completed the Schizotypal Personality Questionnaire (SPQ). The Temperament and Character Inventory (TCI) and a neuropsychological test battery consisting of full versions of the Wechsler Memory Scale-Revised and the Wechsler Adult Intelligence Scale-Revised, and the Wisconsin Card Sorting Test, were also administered to most of the participants. The total SPQ score of those born in winter was significantly higher than that of the remaining participants. Season of birth was not significantly associated with any of the TCI dimensions or cognitive test results. Significant but mild relationships between higher SPQ scores and lower scores on some aspects of IQ were observed. These results support the notion that schizotypy and schizophrenia are neurodevelopmental conditions on the same continuum.

© 2011 Elsevier Ireland Ltd. All rights reserved.

1. Introduction

Schizotypy refers to latent personality organization that indicates an individual's proneness to psychosis and, in particular, to schizophrenia (Raine et al., 1995). The dimensional model of schizotypal personality posits that the degree of schizotypal traits varies on a continuum where normality lies on one extreme, non-clinical to clinical schizotypy in the middle, and clinically expressed schizophrenia on the opposite extreme (Claridge, 1985, Kendler et al., 1991). In accord with this view, several lines of evidence have demonstrated a range of abnormalities in relation to schizotypal personality that are intrinsically similar to those seen in schizophrenia (Siever and Davis, 2004), such as neurophysiological (O'Driscoll et al., 1998; Kiang and Kutas, 2005), neurocognitive (Lenzenweger and Korfine, 1994; Gooding et al., 2006), neuroendocrinological (Mitropoulou et al., 2004; Hori et al., 2011) and neuroimaging (Folley and Park, 2005; Hori et al., 2008a) abnormalities.

On the other hand, little has been done to identify early-life origins that predict greater schizotypal traits in adulthood, although it is now well established that schizophrenia is to some extent associated with such origins. Among a variety of factors that originate early in life,

season of birth has been extensively studied in the epidemiology of schizophrenia, with most studies reporting a slight (approximately 10%) excess of winter/early spring birth in patients with schizophrenia (reviewed in Torrey et al., 1997; Davies et al., 2003). To better understand the etiology of and risk factors for schizophrenia in light of the dimensional model of this disorder, it would be of importance to investigate the possible effect of season of birth on schizotypal traits. To our knowledge, there have been four studies that shed light on this topic. Reid and Zborowski (2006), using a sample of undergraduate students from the Northeast United States, found significantly higher scores on the Perceptual-Aberration and Magical-Ideation scale, developed by Chapman and his colleagues, in individuals born in spring than those born in the other seasons. Kirkpatrick et al. (2008) found in undergraduates from the middle-eastern United States that June/July birth was associated with a proxy measure for the deficit syndrome, which was defined by combining the Chapman's Social Anhedonia Scale and the Beck Depression Inventory. Lahti et al. (2009), using a large cohort consisting of approximately 5000 people born in Northern Finland in 1966, showed that winter/autumn birth, in addition to several other early-life characteristics, predicted augmented negative schizotypal traits (as assessed with the Chapman's Physical Anhedonia Scale) in women. More recently, Cohen and Najolia (2011) screened more than 25,000 university students from the southern United States and showed that season of birth of individuals who scored extremely high on the Schizotypal Personality

* Corresponding author. Tel.: +81 42 341 2711; fax: +81 42 346 1744.
E-mail address: hori@ncnp.go.jp (H. Hori).

Questionnaire (SPQ, Raine, 1991) did not differ from that of those whose scores were less than one standard deviation above the mean. Taken together, findings to date on the association between season of birth and schizotypal traits have not been consistent and thus await further investigations.

Season of birth has also been reported to be associated with other personality traits, including temperament/character dimensions (Chotai et al., 2001, 2002, 2009; Kamata et al., 2009). Studies including ours have shown that temperament and character of patients with schizophrenia are markedly different from those of healthy controls, such that these patients, compared to healthy controls, exhibit lower novelty seeking, self-directedness and cooperativeness and higher harm avoidance (Guillem et al., 2002; Hori et al., 2008b). In addition, temperament and character personality dimensions have been shown to correlate with schizotypal personality (Daneluzzo et al., 2005; Bora and Veznedaroglu, 2007).

There also exists evidence that certain aspects of cognitive function could be affected by season of birth (Martin et al., 2004; McGrath et al., 2006; Gobet and Chassy, 2008). Interestingly, some studies have found an association between superior cognitive performance and winter/spring birth (McGrath et al., 2006; Gobet and Chassy, 2008), which might be counterintuitive to the fact that neurocognitive impairments are a core feature of schizophrenia. Another line of research has looked at the relationships between personality traits and neurocognitive functioning. As for the association between schizotypy and neurocognition, a number of studies in psychometrically identified schizotypes have, albeit not entirely unequivocally, found this condition to be associated with compromised functioning in various cognitive domains, including sustained attention (Lenzenweger, 2001; Gooding et al., 2006), spatial working memory (Park and McTigue, 1997), and executive function as assessed with the Wisconsin Card Sorting Test (WCST, Lenzenweger and Korfine, 1994; Daneluzzo et al., 1998). Although the relationship between temperament/character and cognition is less well studied, several studies have examined this relation among various psychiatric conditions. For instance, Bergvall et al. (2003) reported that higher self-directedness and cooperativeness were significantly associated with less errors in an attentional set-shifting task in a sample consisting of incarcerated offenders, correctional officers and medical aides. Similarly, Smith et al. (2008) showed that self-directedness and cooperativeness were strongly positively correlated with working memory and crystallized intelligence in non-psychotic siblings.

In this context, the present study sought to explore the associations of season of birth with schizotypal personality traits, temperament/character dimensions and cognitive function. In addition, we also attempted to clarify the relationships between schizotypal traits, temperament/character and cognitive functioning.

2. Methods

2.1. Participants

Participants were 451 Japanese adults (age range: 19–73 years) who resided in the western part of Tokyo. They were recruited between 2006 and 2010 from the community through advertisements in free local magazines and our website announcement, and also from hospital staff and their associates through flyers and by word of mouth. At the first visit, participants were interviewed using the Japanese version of the Mini-International Neuropsychiatric Interview (Sheehan et al., 1998; Otsubo et al., 2005) by a research psychiatrist, and only those who demonstrated no current Axis I psychiatric disorders were enrolled in the study. In addition, those individuals who demonstrated one or more of the following conditions in a non-structured interview performed by an experienced psychiatrist were excluded: past or current regular contact to psychiatric services, having a history of regular use of psychotropics or substance abuse/dependence, presenting other obvious self-reported signs of past primary psychotic and mood disorders, and having a prior medical history of central nervous system disease or severe head injury. The present experiments on our participants were conducted in accordance with the Declaration of Helsinki. After the nature of the study procedures had been fully explained, written informed consent was obtained from all participants. The study was approved by the ethics committee of the National Center of Neurology and Psychiatry, Japan.

2.2. Personality assessment

Personality was assessed with two self-report questionnaires, which were distributed to each participant at our laboratory. He/she was allowed to take as much time as needed to complete the questionnaires, then returned them to us by mail or by hand.

2.2.1. Schizotypal Personality Questionnaire (SPQ)

The SPQ (Raine, 1991) is a 74-item validated self-report questionnaire with a “yes/no” response format that incorporates DSM-III-R (American Psychiatric Association, 1987) criteria for a diagnosis of schizotypal personality disorder (SPD). All items endorsed “yes” are scored 1 point. The questionnaire consists of nine subscales, which have been found to load onto three factors: cognitive–perceptual (comprising the “ideas of reference,” “odd beliefs/magical thinking,” “unusual perceptual experiences” and “suspiciousness/paranoid ideation” subscales), interpersonal (“social anxiety,” “no close friends,” “constricted affect,” and “suspiciousness/paranoid ideation”), and disorganized (“eccentric/odd behavior and appearance” and “odd speech”) factors (Raine et al., 1994). We employed the Japanese version of the SPQ (Fujiwara, 1993), reliability and validity of which had been demonstrated to be similar to those of the original version (Raine, 1991). All participants completed this questionnaire.

2.2.2. Temperament and Character Inventory (TCI)

TCI (Cloninger et al., 1993) is a 240-item (including 14 items which are not analyzed) self-report questionnaire; each item requires a true/false answer. The term temperament refers to automatic emotional reactions to subjective experiences that may be genetically transmitted and therefore stable over time. Four dimensions of temperament are distinguished: novelty seeking, harm avoidance, reward dependence, and persistence. Novelty seeking, harm avoidance, and reward dependence were assumed to relate to dopaminergic, serotonergic, and noradrenergic neurotransmission, respectively (Cloninger, 1987). The term character refers to concepts pertaining to the individual, focusing on personal differences in intentions, decisions and values. Three dimensions of character are distinguished: self-directedness, cooperativeness, and self-transcendence. The reliability and validity of the original American version of the TCI have been established (Cloninger et al., 1993; Svrakic et al., 1993). The Japanese version of the TCI translated and validated by Kijima et al. (1996, 2000) was used in the present study. Of the total 451 participants, 443 (98.2%) completed the TCI.

2.3. Cognitive test battery

A neurocognitive test battery, comprising full versions of the Wechsler Memory Scale-Revised (WMS-R, Wechsler, 1987; Sugishita, 2001) and the Wechsler Adult Intelligence Scale-Revised (WAIS-R, Wechsler, 1981; Shinagawa et al., 1990), and the Wisconsin Card Sorting Test (WCST, Heaton, 1981; Kashima et al., 1987), was administered. Using these tests, we measured verbal memory, visual memory, general memory, attention/concentration, delayed recall (WMS-R), verbal intelligence quotient (IQ) and its six subtests, performance IQ and its five subtests, full-scale IQ (WAIS-R), and executive function (WCST). Outcome measures of the WCST comprised the number of categories achieved, total errors, and perseverative errors. Perseverative errors included two types of perseveration: inappropriate repetitions of a response that sticks to the previously achieved category (i.e., perseverative errors of Milner type; PEM) and repetitions of the immediately preceding incorrect response (i.e., perseverative errors of Nelson type; PEN). The WMS-R, WAIS-R and WCST were completed by 415 (92.0%), 379 (84.0%) and 408 (90.5%) of the total 451 participants, respectively.

2.4. Analysis

Information on the date of birth was obtained for all participants. Based on this information, two types of the four seasons were considered; one criterion (“Traditional criterion”) was the traditional Japanese definition of the four seasons (i.e., March, April and May into spring; June, July and August into summer; September, October and November into autumn; December, January and February into winter), and the other criterion (“Astronomical criterion”) was the definition of the four seasons taking account of the equinoxes (i.e., March 22–June 21 into spring; June 22–September 21 into summer; September 22–December 21 into autumn; December 22–March 21 into winter). We herein considered these two definitions of the four seasons because previous studies investigating the association between season of birth and schizophrenia/schizotypy have employed different definitions, such that some have used the Traditional criterion (e.g., Takei et al., 1995; Kunugi et al., 1997) while others the Astronomical criterion (e.g., Reid and Zborowski, 2006; Cohen and Najolia, 2011). In the present report, the Traditional criterion was used unless otherwise specified and the Astronomical criterion was used for confirmation purpose.

Averages are reported as means \pm Standard deviation (S.D.). Categorical variables were compared using the χ^2 test. The *t*-test or analysis of variance (ANOVA) was used to examine differences between groups. Pearson's *r* was used to examine correlations. Partial correlation analysis was used to examine correlations, controlling for potentially confounding variables. The analysis of covariance (ANCOVA) was performed to compare scores controlling for confounders as defined below. Statistical significance was set at two-tailed $p < 0.05$. Analyses were performed using the Statistical Package for the Social Sciences (SPSS) version 18.0 (SPSS Japan, Tokyo).

3. Results

3.1. Demographic characteristics and schizotypal personality

Of the 451 participants, 112 were male and 339 female. Mean age of the participants was 45.2 ± 15.2 years. Mean years of education was 14.9 ± 2.6 . Numbers of participants who were born in spring, summer, autumn and winter (based on the "Traditional criterion") were 98, 113, 106 and 134, respectively. There were no significant differences in age [$F(3,447) = 0.10, p = 0.96$] or sex [$\chi^2(3) = 6.02, p = 0.11$] distribution depending on season of birth. Numbers of participants who were born in January, February, March, April, May, June, July, August, September, October, November and December were 42, 53, 41, 31, 26, 38, 32, 43, 32, 46, 28 and 39, respectively. There were no significant differences in age [$F(11,439) = 1.52, p = 0.12$] or sex [$\chi^2(11) = 12.5, p = 0.12$] distribution depending on month of birth. Mean scores of the cognitive–perceptual factor, interpersonal factor, disorganized factor, and the total SPQ score were $4.0 \pm 4.2, 6.5 \pm 5.6, 3.4 \pm 3.2,$ and $12.9 \pm 10.0,$ respectively. Males scored significantly higher than females in the interpersonal factor ($t = 2.4, d.f. = 162, p = 0.016$), but they did not differ in the other two factors or the total SPQ score (all $p > 0.3$). Age showed a significant negative correlation with the disorganized factor ($r = -0.22, p < 0.001$) and total SPQ score ($r = -0.12, p = 0.009$), while years of education did not show any significant correlations with the SPQ indices (all $p > 0.3$). Therefore, we decided to control for age and sex in the ANCOVA model as these variables could potentially confound the association between season of birth and schizotypal traits.

3.2. Correlations between schizotypal traits and temperament/character dimensions

Table 1 shows the partial correlations, controlling for age and sex, between the SPQ indices and seven dimensions of the TCI. The SPQ indices were positively correlated with harm avoidance and self-transcendence while they were negatively correlated with novelty seeking, reward dependence, self-directedness and cooperativeness.

3.3. Association of season of birth with schizotypal trait, temperament/character, and cognitive function

Fig. 1 shows the relationship between birth season (based on the "Traditional criterion") and the total SPQ score in the whole sample. Mean total SPQ scores of those born in spring, summer, autumn, and winter were $12.6 \pm 9.3, 12.5 \pm 8.9, 11.0 \pm 9.7,$ and $15.0 \pm 11.4,$ respectively. The ANCOVA, controlling for age and sex, revealed that the total SPQ score was significantly different between these four seasonal groups [$F(3,445) = 3.6, p = 0.014$]; post-hoc analysis with Bonferroni correction revealed that the total SPQ score was significantly higher in those individuals born in winter than those born in autumn (estimated mean difference = 4.09, 95% confidence interval = 0.69 to 7.50, $p = 0.009$). In addition, the total SPQ score was significantly higher in the winter-born individuals than in the remaining individuals (15.0 ± 11.4 vs. 12.0 ± 9.3 ; $t = 2.66, d.f. = 211,$




Fig. 1. Comparisons of the total SPQ score between individuals born in each of the four seasons (based on the Traditional criterion). * $p < 0.05$ (according to the ANCOVA with post-hoc analysis with Bonferroni correction).

$p = 0.008$). Taking into account that Lahti et al. (2009) found the significant association between winter/autumn birth and schizotypal traits only in women, the similar analyses, including the ANCOVA with age as a covariate and the t -test, were repeated separately for males and females. For males, the ANCOVA revealed that the main effect of season of birth was not significant [$F(3,107) = 0.86, p = 0.46$]. The total SPQ score was not significantly different between winter-born men and the remaining men (15.1 ± 11.4 vs. 13.1 ± 10.7 ; $t = 0.85, d.f. = 110, p = 0.40$). For females, the ANCOVA revealed that the total SPQ score was significantly different between these four seasonal groups [$F(3,334) = 3.9, p = 0.009$]; post-hoc analysis with Bonferroni correction revealed that the total SPQ score was significantly higher in those individuals born in winter than those born in autumn (estimated mean difference = 4.64, 95% confidence interval = 0.86 to 8.43, $p = 0.007$). The total SPQ score was significantly higher in the winter-born women than in the remaining women (14.9 ± 11.4 vs. 11.6 ± 8.7 ; $t = 2.94, d.f. = 162.5, p = 0.009$).

When the Astronomical criterion was used, mean total SPQ scores of those born in spring, summer, autumn, and winter were $12.3 \pm 8.3, 12.4 \pm 9.7, 11.6 \pm 9.0,$ and $14.8 \pm 11.8,$ respectively. The similar ANCOVA again revealed the significant difference in the total SPQ score between these four seasonal groups [$F(3,445) = 3.0, p = 0.029$]; post-hoc analysis with Bonferroni correction revealed that the total SPQ score was significantly higher in those individuals born in winter than those born in autumn (estimated mean difference = 3.53, 95% confidence interval = 0.15 to 6.91, $p = 0.035$). The total SPQ score was significantly higher in the winter-born individuals than in the remaining individuals (14.8 ± 11.8 vs. 12.1 ± 9.0 ; $t = 2.65, d.f. = 206, p = 0.018$).

Supplementary Fig. 1 shows the relationship between birth month and the total SPQ score in the whole sample. This figure also presents the deviance of temperature of each month from the annual average temperature in Tokyo (calculated as "average temperature of individual month" – "annual average temperature") averaged between 1970 and 2000 according to statistics reported by the Japan Meteorological Agency; thus, peaks and valleys of this line graph indicate severe and mild climates, respectively. In this figure we can

Table 1

Partial correlations between schizotypal personality and temperament/character dimensions, controlling for age and sex ($n = 443$).

	Novelty seeking	Harm avoidance	Reward dependence	Persistence	Self-directedness	Cooperativeness	Self-transcendence
Cognitive–perceptual factor	–0.08	0.15**	–0.19***	0.11*	–0.38***	–0.19***	0.37***
Interpersonal factor	–0.24***	0.53***	–0.37***	–0.03	–0.58***	–0.37***	0.02
Disorganized factor	–0.03	0.28***	–0.24***	0.01	–0.47***	–0.24***	0.14**
Total SPQ score	–0.16**	0.40**	–0.31***	0.02	–0.56***	–0.30***	0.21***

Each figure represents partial correlation coefficient (r) ($d.f. = 439$).

* $p < 0.05$ (2-tailed).

** $p < 0.01$ (2-tailed).

*** $p < 0.001$ (2-tailed).

Table 2

Partial correlations of SPQ three factors and total score with neurocognitive test results, controlling for age and sex.

	Verbal memory ^a	Visual memory ^a	General memory ^a	Attention/concentration ^a	Delayed recall ^a	Information ^b	Digit span ^b	Vocabulary ^b	Arithmetic ^b	Comprehension ^b
Cognitive-perceptual factor	−0.05	−0.06	−0.03	−0.08	−0.03	−0.05	0.01	0.00	−0.02	−0.06
Interpersonal factor	−0.08	−0.02	−0.07	−0.02	−0.02	−0.05	−0.02	−0.04	−0.06	−0.14**
Disorganized factor	−0.05	−0.06	−0.06	−0.08	−0.04	−0.03	−0.06	−0.01	−0.08	−0.11*
Total SPQ score	−0.07	−0.06	−0.07	−0.06	−0.03	−0.06	−0.02	−0.02	−0.07	−0.13*

Each figure represents partial correlation coefficient (*r*).**p*<0.05; ***p*<0.01 (2-tailed).^a *n* = 415, d.f. = 411.^b *n* = 379, d.f. = 375.^c *n* = 408, d.f. = 404.

see the general tendency that the higher bars correspond to the peaks of the line graph, indicating that those born in more severe climates, i.e., January, August and December, demonstrated greater schizotypal traits. Indeed, correlation between the temperature deviance from the annual average and the SPQ total score was significant ($r = 0.10$, $p = 0.028$).

Supplementary Figs. 2–5 show the relationships of four birth seasons (based on the “Traditional criterion”) with seven dimensions of the TCI (Fig. S2), five memory indices as measured by the WMS-R (Fig. S3), three IQ indices as measured by the WAIS-R (Fig. S4), and four indices of executive function as measured by the WCST (Fig. S5). The ANCOVA controlling for age and sex showed that the four seasonal groups did not differ in any of the seven TCI dimensions (all $p > 0.1$) or in any of the neurocognitive test results (i.e., indices of the WMS-R, WAIS-R, and WCST) (all $p > 0.05$). These relationships remained non-significant when the same analyses were repeated using the “Astronomical criterion” of season.

3.4. Relationships of schizotypal trait with cognitive function

Table 2 presents correlations between the SPQ indices and cognitive test results, controlling for age and sex. Comprehension and digit symbol subtests of the WAIS-R showed significant, albeit weak (correlation coefficients ranging from -0.11 to -0.14), negative correlations with the interpersonal and disorganized factors and the total SPQ score, while there were no significant correlations of memory indices of the WMS-R or executive function indices of the WCST with any indices of the SPQ.

3.5. Relationships of temperament/character with cognitive function

Table 3 shows correlations between the seven TCI dimensions and cognitive test results, controlling for age and sex. Harm avoidance was significantly negatively, while self-directedness and cooperativeness were significantly positively, associated with several memory and IQ measures including verbal memory, general memory, and a number of

IQ subtests, especially those belonging to verbal IQ. Persistence was associated with better performance on the WCST.

4. Discussion

We can summarize the main findings as follows. A significant association of schizotypal traits with winter birth was found, while season of birth was not significantly associated with any of the TCI dimensions or neurocognitive test results. We also found significant but mild relationships between higher SPQ scores and lower performance in two subtests of IQ.

The majority of studies in schizophrenia, in particular those conducted in the Northern Hemisphere, have reported that there is a winter (or winter/early spring) birth excess (Torrey et al., 1997; Davies et al., 2003), and such birth seasonality has also been found in Japanese patients (Kunugi et al., 1997; Tatsumi et al., 2002). However, this season of birth effect has not been replicated in the Southern Hemisphere (reviewed in McGrath and Welham, 1999). Taking into account that the countries in the Southern Hemisphere where these studies have been conducted are closer to the equator than those in the Northern Hemisphere, one of the possible explanations for this discrepancy is considered to relate to the latitude, i.e., the higher the latitude, the greater the season of birth effect (McGrath and Welham, 1999; Davies et al., 2003). The observed association between winter birth and greater SPQ score in our non-clinical population is compatible with the evidence in schizophrenia obtained in the Northern Hemisphere, supporting the dimensionality between schizotypal personality and schizophrenia. The present result of the significant association in women also accords with a recent study in Finland showing that winter/autumn birth in women predicts augmented schizotypal traits in adulthood (Lahti et al., 2009). For men, however, the absence of a significant association between winter birth and SPQ score in the present study might be due to the type II error since the mean total SPQ score was higher in winter-born men than in the remaining men (i.e., 15.1 ± 11.4 vs. 13.1 ± 10.7). On the other hand, as mentioned earlier, findings from the three other precedent studies that have investigated the season of birth effect on

Table 3

Partial correlations between TCI seven dimensions and neurocognitive test results, controlling for age and sex.

	Verbal memory ^a	Visual memory ^a	General memory ^a	Attention/concentration ^a	Delayed recall ^a	Information ^b	Digit span ^b	Vocabulary ^b	Arithmetic ^b	Comprehension ^b
Novelty seeking	0.06	0.00	0.07	−0.09	−0.01	0.05	−0.05	0.07	−0.01	0.14**
Harm avoidance	−0.15**	0.01	−0.14**	−0.01	−0.09	−0.04	−0.01	−0.05	−0.08	−0.14**
Reward dependence	0.03	0.05	0.03	−0.04	0.03	−0.10	0.04	−0.08	−0.05	−0.02
Persistence	−0.01	−0.04	0.02	0.00	0.00	−0.01	0.04	0.04	0.01	0.06
Self-directedness	0.13**	0.02	0.12*	0.06	0.12*	0.08	0.07	0.09	0.14**	0.20***
Cooperativeness	0.12*	0.03	0.10*	0.01	0.07	0.03	0.09	0.09	0.00	0.13*
Self-transcendence	−0.03	−0.07	−0.01	−0.01	−0.02	−0.06	0.04	0.03	−0.04	−0.04

Each figure represents partial correlation coefficient (*r*).**p*<0.05; ***p*<0.01; ****p*<0.001 (2-tailed).^a *n* = 409, d.f. = 405.^b *n* = 376, d.f. = 372.^c *n* = 402, d.f. = 398.

Similarities ^b	Picture completion ^b	Picture arrangement ^b	Block design ^b	Object assembly ^b	Digit symbol ^b	Verbal IQ ^b	Performance IQ ^b	Full-scale IQ ^b	WCST category ^c	WCST total errors ^c	WCST PEM ^c	WCST PEN ^c
−0.10	0.02	0.02	−0.04	−0.04	−0.08	−0.06	−0.03	−0.05	0.01	−0.03	0.02	−0.02
−0.09	−0.03	0.02	−0.06	0.02	−0.11*	−0.10	−0.03	−0.08	0.00	−0.02	0.02	−0.05
−0.07	−0.03	0.00	−0.01	0.01	−0.14**	−0.08	−0.04	−0.07	−0.01	−0.02	0.02	0.01
−0.10	−0.02	0.02	−0.04	0.00	−0.13**	−0.10	−0.04	−0.08	0.00	−0.03	0.02	−0.02

schizotypy are not in line with the present one; two studies (Reid and Zborowski, 2006; Kirkpatrick et al., 2008) reported different relationships between season of birth and schizotypy from the present one, and one study (Cohen and Najolia, 2011) did not find any such significant association although this study observed that no less than 60% of individuals within the schizotypy group reporting a diagnosis of schizophrenia or prior hospitalization had been born during winter months. Given that the four studies (Reid and Zborowski, 2006; Kirkpatrick et al., 2008; Lahti et al., 2009) including the present one that found any significant relationship between season of birth and schizotypy were conducted in higher latitude regions of 35° to 60° whereas the study by Cohen and Najolia (2011) was conducted in a subtropical region with relatively mild winters, this discrepancy may have stemmed, at least partly, from the differences in latitude, as in the aforementioned schizophrenia literature.

Possible mechanisms underlying the association between season of birth and schizophrenia have been speculated, and a variety of seasonal factors, such as ambient temperature, viral infections (e.g., influenza) and vitamins, have been implicated (reviewed in Tochigi et al., 2004). Among these, the ambient temperature might be a promising factor that explains the winter/early spring birth excess in schizophrenia patients (Tochigi et al., 2004). We found that January, August and December, when the ambient temperature is either extremely hot or cold, were the top three months in terms of the increased likelihood of giving birth to those with greater schizotypal traits. In keeping with this, a summer birth excess in patients with deficit schizophrenia has been reported (Kirkpatrick et al., 2002; Messias et al., 2004).

Concerning the association between season of birth and temperamental/character personality dimensions, previous studies have reported significant effects of season of birth on certain temperament and/or character dimensions. Chotai et al. (2001) found in a Swedish adult cohort that those individuals born during February to April were significantly more likely than those born from October to January to have high novelty seeking among women and to have high persistence among men. Chotai et al. (2009) obtained a similar finding in a Finnish adult sample that women born in summer had significantly higher novelty seeking than women born in winter. By

contrast, Chotai et al. (2002) observed in Swedish adolescents that novelty seeking was significantly higher for females born from October to January as compared to females born otherwise. Kamata et al. (2009) found in a Japanese adult sample that higher ambient temperature at birth month was related to higher scores of self-directedness and persistence in females. These previous findings, though somewhat variable, suggest that certain temperamental/character dimensions could be affected by season of birth. In the present study, however, we did not find any significant association between season of birth and temperament/character dimensions. These varied findings may be due to sample characteristics (e.g., age, ethnicity, and geographic area), and more studies are therefore required to clarify this association.

Several lines of evidence have suggested that season of birth is also associated with cognitive function, although the findings are again mixed. Some studies reported that winter/spring birth was associated with better scores on the Wechsler Intelligence performance and full-scale IQs at age 7 (McGrath et al., 2006) and with higher proportion of expert chess players (Gobet and Chassy, 2008), whereas others found superior intellectual functioning in individuals born in summer (Gotoda, 1995; Bibby et al., 1996). In contrast, we did not observe any significant associations between season of birth and cognitive functioning. It should be noted, however, that the previous studies and the present one employed quite different samples and cognitive measures to assess participants' cognitive abilities.

We examined the correlation between schizotypal personality and temperament/character, and found a number of significant correlations between the three factors pertaining to schizotypy and temperament/character dimensions (Table 1). The results are largely consistent with those from two previous studies (Daneluzzo et al., 2005; Bora and Veznedaroglu, 2007), both of which demonstrated that cognitive-perceptual and disorganized factors of the SPQ correlated negatively with self-directedness and positively with self-transcendence, and that interpersonal factor of the SPQ correlated positively with harm avoidance and negatively with self-directedness.

With respect to the association between personality and cognitive function, we found significant but weak negative correlations between SPQ scores and comprehension and digit symbol subtests

Similarities ^b	Picture completion ^b	Picture arrangement ^b	Block design ^b	Object assembly ^b	Digit symbol ^b	Verbal IQ ^b	Performance IQ ^b	Full-scale IQ ^b	WCST category ^c	WCST total errors ^c	WCST PEM ^c	WCST PEN ^c
0.00	0.07	0.11*	0.01	0.09	−0.03	0.04	0.07	0.06	0.01	0.01	0.04	0.06
−0.03	−0.07	0.04	−0.07	−0.03	−0.08	−0.09	−0.05	−0.09	−0.06	0.06	0.02	−0.02
0.02	0.01	0.09	0.01	−0.02	0.00	−0.04	0.02	−0.01	0.00	0.02	0.04	0.04
0.04	0.08	0.01	0.02	−0.10*	0.07	0.05	0.00	0.03	0.12*	−0.13**	−0.11*	−0.08
0.16**	0.01	−0.06	0.10	−0.02	0.18***	0.18***	0.06	0.15**	0.05	−0.04	−0.03	0.02
0.15**	0.11*	0.02	0.11*	0.08	0.05	0.12*	0.09	0.13*	0.00	0.00	0.04	0.04
−0.02	0.06	0.03	0.06	−0.02	−0.01	−0.01	0.00	0.01	0.03	−0.02	0.00	0.03

of the WAIS-R. As described earlier, previous studies have demonstrated that schizotypal traits, even at a non-clinical level, are associated with mild impairments in cognitive domains including sustained attention, spatial working memory, and executive functioning. What is more relevant to the present finding is that recent studies have reported the association between psychometrically defined schizotypy and mild impairments in some aspects of IQ (Matheson and Langdon, 2008; Noguchi et al., 2008). In addition, the present finding may correspond well to the evidence that processing speed as measured by the digit symbol coding task is the most severely impaired cognitive domain in schizophrenia (Dickinson et al., 2007). In the present study, temperament/character dimensions, in particular harm avoidance, self-directedness and cooperativeness, were associated with performances on several cognitive domains including memory and IQ. In line with the present finding, previous studies have reported significant associations between higher self-directedness and cooperativeness on the one hand and better cognitive performance on the other (Bergvall et al., 2003; Smith et al., 2008).

Findings reported here should be considered in the context of a number of limitations. First, the present finding on the association between season of birth and schizotypy obtained in Japan may not be easily extrapolated to another location, particularly to the southern hemisphere. Second, given the high number of the correlational analyses between personality measures and cognitive indices (Tables 2 and 3), some stringent measures may have been needed to correct for the multiple testing. Nevertheless, we would like to note that our significant findings on the associations between specific personality traits and mildly impaired cognitive functioning were generally in harmony with previous ones (Bergvall et al., 2003; Matheson and Langdon, 2008; Noguchi et al., 2008; Smith et al., 2008), as discussed above. Third, since women were overrepresented in our sample, it is possible that the present findings are applicable only to women. The fourth limitation could be the relatively low mean total SPQ score of 12.9 (S.D. = 10.0) of our sample, given that the mean total SPQ scores of non-clinical populations have been reported to be around 20 in the majority of prior studies, most of which were conducted in Western countries. This discrepancy is likely to have been derived from ethnic differences (Western vs. Japanese/Asian). Indeed, mean total SPQ scores in healthy Japanese populations have been consistently shown to be relatively low, ranging from 8.1 to 12.9 (Someya et al., 1994; Wang et al., 2004; Hori et al., 2008a; Noguchi et al., 2008; Takahashi et al., 2010). Another plausible explanation for the discrepancy in SPQ scores between these samples might be the difference in mean age of participants, i.e., college students in most of the prior studies vs. adults in the present study. In a study of Chen et al. (1997), for example, mean total SPQ scores of Taiwanese adolescents and adults were 20.6 and 12.9, respectively. Thus, the present sample could be deemed representative of non-clinical Asian adults. Finally, although we targeted the adult population, most of the previous studies investigating the correlates of non-clinical schizotypy have targeted students. From the standpoint of the risk of developing schizophrenia, students may be a better suited population; however, we believe that our dimensional approach has its own merits. To further explore the dimensional model and to identify the risk population for the development of psychosis, future studies that investigate the association between season of birth and schizotypal traits among clinical populations (e.g., SPD patients with and without family history of schizophrenia) as well as student populations are needed.

In summary, the present study found that schizotypal traits in a non-clinical population were associated with an excess of winter birth, whereas season of birth was not significantly associated with temperament/character personality dimensions or neurocognition. Schizotypal traits were also associated with mild impairments in some aspects of intellectual functioning. These results point to the etiological similarity between schizotypal personality and schizo-

phrenia-spectrum disorders, potentially supporting the notion that these conditions are on the same continuum. From the perspective of public health, such attempts to identify early signs that confer vulnerability to schizotypy as well as schizophrenia-spectrum disorders might provide an important clue to prevention of and early intervention for schizophrenia.

Acknowledgements

We would like to thank all volunteers who participated in the study. This study was supported by Health and Labor Sciences Research Grants (Comprehensive Research on Disability, Health, and Welfare), Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (JSPS), Intramural Research Grant for Neurological and Psychiatric Disorders of NCNP, CREST, JST (H.K.), and Grant-in-Aid for Young Scientists from the JSPS (H.H.).

Appendix A. Supplementary data

Supplementary data to this article can be found online at doi:10.1016/j.psychres.2011.07.028.

References


- American Psychiatric Association, 1987. *Diagnostic and Statistical Manual of Mental Disorders*, revised 3rd ed. American Psychiatric Association, Washington, D. C.
- Bergvall, A.H., Nilsson, T., Hansen, S., 2003. Exploring the link between character, personality disorder, and neuropsychological function. *European Psychiatry* 18, 334–344.
- Bibby, P.A., Lamb, S.J., Leyden, G., Wood, D., 1996. Season of birth and gender effects in children attending moderate learning difficulty schools. *British Journal of Educational Psychology* 66, 159–168.
- Bora, E., Veznedaroglu, B., 2007. Temperament and character dimensions of the relatives of schizophrenia patients and controls: the relationship between schizotypal features and personality. *European Psychiatry* 22, 27–31.
- Chen, W.J., Hsiao, C.K., Lin, C.C., 1997. Schizotypy in community samples: the three-factor structure and correlation with sustained attention. *Journal of Abnormal Psychology* 106, 649–654.
- Chotai, J., Forsgren, T., Nilsson, L.G., Adolfsson, R., 2001. Season of birth variations in the temperament and character inventory of personality in a general population. *Neuropsychobiology* 44, 19–26.
- Chotai, J., Jonasson, M., Hägglöf, B., Adolfsson, R., 2002. The Temperament Scale of Novelty Seeking in adolescents shows an association with season of birth opposite to that in adults. *Psychiatry Research* 111, 45–54.
- Chotai, J., Joukamaa, M., Taanila, A., Lichtermann, D., Miettunen, J., 2009. Novelty seeking among adult women is lower for the winter borns compared to the summer borns: replication in a large Finnish birth cohort. *Comprehensive Psychiatry* 50, 562–566.
- Claridge, G.S., 1985. *Origins of Mental Illness*. Blackwell, Oxford.
- Cloninger, C.R., 1987. A systematic method for clinical description and classification of personality variants. A proposal. *Archives of General Psychiatry* 44, 573–588.
- Cloninger, C.R., Svrakic, D.M., Przybeck, T.R., 1993. A psychobiological model of temperament and character. *Archives of General Psychiatry* 50, 975–990.
- Cohen, A.S., Najolia, G.M., 2011. Birth characteristics and schizotypy: evidence of a potential “second hit”. *Journal of Psychiatric Research* 45, 955–961.
- Daneluzzo, E., Bustini, M., Stratta, P., Casacchia, M., Rossi, A., 1998. Schizotypal Personality Questionnaire and Wisconsin Card Sorting Test in a population of DSM-III-R schizophrenic patients and control subjects. *Comprehensive Psychiatry* 39, 143–148.
- Daneluzzo, E., Stratta, P., Rossi, A., 2005. The contribution of temperament and character to schizotypy multidimensionality. *Comprehensive Psychiatry* 46, 50–55.
- Davies, G., Welham, J., Chant, D., Torrey, E.F., McGrath, J., 2003. A systematic review and meta-analysis of Northern Hemisphere season of birth studies in schizophrenia. *Schizophrenia Bulletin* 29, 587–593.
- Dickinson, D., Ramsey, M.E., Gold, J.M., 2007. Overlooking the obvious: a meta-analytic comparison of digit symbol coding tasks and other cognitive measures in schizophrenia. *Archives of General Psychiatry* 64, 532–542.
- Folley, B.S., Park, S., 2005. Verbal creativity and schizotypal personality in relation to prefrontal hemispheric laterality: a behavioral and near-infrared optical imaging study. *Schizophrenia Research* 80, 271–282.
- Fujiwara, T., 1993. The SPQ: a scale for the assessment of schizotypal personality based on DSM-III-R criteria. *Advances in Schizophrenia Research* 3, 21–25 (in Japanese).
- Gobet, F., Chassy, P., 2008. Season of birth and chess expertise. *Journal of Biosocial Science* 40, 313–316.
- Gooding, D.C., Matts, C.W., Rollmann, E.A., 2006. Sustained attention deficits in relation to psychometrically identified schizotypy: evaluating a potential endophenotypic marker. *Schizophrenia Research* 82, 27–37.
- Gotoda, T., 1995. Born in summer? *Nature* 377, 672.
- Guillem, F., Bicu, M., Semkowska, M., Debruille, J.B., 2002. The dimensional symptom structure of schizophrenia and its association with temperament and character. *Schizophrenia Research* 56, 137–147.

- Heaton, R.K., 1981. The Wisconsin Card Sorting Test (Manual). Psychological Assessment Resources, Florida.
- Hori, H., Ozeki, Y., Terada, S., Kunugi, H., 2008a. Functional near-infrared spectroscopy reveals altered hemispheric laterality in relation to schizotypy during verbal fluency task. *Progress in Neuro-Psychopharmacology and Biological Psychiatry* 32, 1944–1951.
- Hori, H., Noguchi, H., Hashimoto, R., Nakabayashi, T., Saitoh, O., Murray, R.M., Okabe, S., Kunugi, H., 2008b. Personality in schizophrenia assessed with the Temperament and Character Inventory (TCI). *Psychiatry Research* 160, 175–183.
- Hori, H., Teraishi, T., Ozeki, Y., Hattori, K., Sasayama, D., Matsuo, J., Kawamoto, Y., Kinoshita, Y., Higuchi, T., Kunugi, H., 2011. Schizotypal personality in healthy adults is related to blunted cortisol responses to the combined dexamethasone/corticotropin-releasing hormone test. *Neuropsychobiology* 63, 232–241.
- Kamata, M., Suzuki, A., Matsumoto, Y., Togashi, H., Otani, K., 2009. Effect of month of birth on personality traits of healthy Japanese. *European Psychiatry* 24, 86–90.
- Kashima, H., Handa, T., Kato, M., Sakura, K., Yokoyama, N., Murakami, M., Shigemori, K., Muramatsu, T., Saito, H., Ooe, Y., Mimura, M., Asai, M., Hosaki, H., 1987. Neuropsychological investigation on chronic schizophrenia—aspects of its frontal functions. In: Takahashi, R., Flor-Henry, P., Gruzelier, J., Niwa, S. (Eds.), *Cerebral Dynamics, Laterality and Psychopathology*. Elsevier, Amsterdam, pp. 337–345.
- Kendler, K.S., Ochs, A.L., Gorman, A.M., Hewitt, J.K., Ross, D.E., Mirsky, A.F., 1991. The structure of schizotypy: a pilot multitrait twin study. *Psychiatry Research* 36, 19–36.
- Kiang, M., Kutas, M., 2005. Association of schizotypy with semantic processing differences: an event-related brain potential study. *Schizophrenia Research* 77, 329–342.
- Kijima, N., Saito, R., Takeuchi, M., Yoshino, A., Ono, Y., Kato, M., Kitamura, T., 1996. Cloninger's seven-factor model of temperament and character and Japanese version of Temperament and Character Inventory (TCI). *Archives of Psychiatric Diagnostic and Clinical Evaluations* 7, 379–399 (in Japanese).
- Kijima, N., Tanaka, E., Suzuki, N., Higuchi, H., Kitamura, T., 2000. Reliability and validity of the Japanese version of the Temperament and Character Inventory. *Psychological Reports* 86, 1050–1058.
- Kirkpatrick, B., Tek, C., Allardyce, J., Morrison, G., McCreadie, R.G., 2002. Summer birth and deficit schizophrenia in Dumfries and Galloway, southwestern Scotland. *American Journal of Psychiatry* 159, 1382–1387.
- Kirkpatrick, B., Messias, E., LaPorte, D., 2008. Schizoid-like features and season of birth in a nonpatient sample. *Schizophrenia Research* 103, 151–155.
- Kunugi, H., Nanko, S., Hayashi, N., Saito, K., Hirose, T., Kazamatsuri, H., 1997. Season of birth of schizophrenics in a recent Japanese sample. *Psychiatry and Clinical Neurosciences* 51, 213–216.
- Lahti, J., Raikkönen, K., Sovio, U., Miettinen, J., Hartikainen, A.L., Pouta, A., Taanila, A., Joukamaa, M., Järvelin, M.R., Veijola, J., 2009. Early-life origins of schizotypal traits in adulthood. *British Journal of Psychiatry* 195, 132–137.
- Lenzenweger, M.F., 2001. Reaction time slowing during high-load, sustained-attention task performance in relation to psychometrically identified schizotypy. *Journal of Abnormal Psychology* 110, 290–296.
- Lenzenweger, M.F., Korfne, L., 1994. Perceptual aberrations, schizotypy, and the Wisconsin Card Sorting Test. *Schizophrenia Bulletin* 20, 345–357.
- Martin, R.P., Foels, P., Clanton, G., Moon, K., 2004. Season of birth is related to child retention rates, achievement, and rate of diagnosis of specific LD. *Journal of Learning Disabilities* 37, 307–317.
- Matheson, S., Langdon, R., 2008. Schizotypal traits impact upon executive working memory and aspects of IQ. *Psychiatry Research* 159, 207–214.
- McGrath, J.J., Welham, J.L., 1999. Season of birth and schizophrenia: a systematic review and meta-analysis of data from the Southern Hemisphere. *Schizophrenia Research* 35, 237–242.
- McGrath, J.J., Saha, S., Lieberman, D.E., Buka, S., 2006. Season of birth is associated with anthropometric and neurocognitive outcomes during infancy and childhood in a general population birth cohort. *Schizophrenia Research* 81, 91–100.
- Messias, E., Kirkpatrick, B., Bromet, E., Ross, D., Buchanan, R.W., Carpenter Jr., W.T., Tek, C., Kendler, K.S., Walsh, D., Dollfus, S., 2004. Summer birth and deficit schizophrenia: a pooled analysis from 6 countries. *Archives of General Psychiatry* 61, 985–989.
- Mitropoulou, V., Goodman, M., Sevy, S., Elman, I., New, A.S., Iskander, E.G., Silverman, J.M., Breier, A., Siever, L.J., 2004. Effects of acute metabolic stress on the dopaminergic and pituitary–adrenal axis activity in patients with schizotypal personality disorder. *Schizophrenia Research* 70, 27–31.
- Noguchi, H., Hori, H., Kunugi, H., 2008. Schizotypal traits and cognitive function in healthy adults. *Psychiatry Research* 161, 162–169.
- O'Driscoll, G.A., Lenzenweger, M.F., Holzman, P.S., 1998. Antisaccades and smooth pursuit eye tracking and schizotypy. *Archives of General Psychiatry* 55, 837–843.
- Otsubo, T., Tanaka, K., Koda, R., Shinoda, J., Sano, N., Tanaka, S., Aoyama, H., Mimura, M., Kamijima, K., 2005. Reliability and validity of Japanese version of the Mini-International Neuropsychiatric Interview. *Psychiatry and Clinical Neurosciences* 59, 517–526.
- Park, S., McTigue, K., 1997. Working memory and the syndromes of schizotypal personality. *Schizophrenia Research* 26, 213–220.
- Raine, A., 1991. The SPQ: a scale for the assessment of schizotypal personality based on DSM-III-R criteria. *Schizophrenia Bulletin* 17, 555–564.
- Raine, A., Reynolds, C., Lencz, T., Scerbo, A., Triphon, N., Kim, D., 1994. Cognitive-perceptual, interpersonal, and disorganized features of schizotypal personality. *Schizophrenia Bulletin* 20, 191–201.
- Raine, A., Lencz, T., Mednick, S.A., 1995. *Schizotypal Personality*. Cambridge University Press, Cambridge.
- Reid, H.M., Zborowski, M.J., 2006. Schizophrenia-proneness, season of birth and sleep: elevated schizotypy scores are associated with spring births and extremes of sleep. *Personality and Individual Differences* 41, 1185–1193.
- Sheehan, D.V., Lecrubier, Y., Sheehan, K.H., Amorim, P., Janavs, J., Weiller, E., Hergueta, T., Baker, R., Dunbar, G.C., 1998. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. *Journal of Clinical Psychiatry* 59 (suppl. 20), 22–57.
- Shinagawa, F., Kobayashi, S., Fujita, K., Maekawa, H., 1990. Japanese Wechsler Adult Intelligence Scale-Revised. Nihonbunkakagakusha, Tokyo, in Japanese.
- Siever, L.J., Davis, K.L., 2004. The pathophysiology of schizophrenia disorders: perspectives from the spectrum. *American Journal of Psychiatry* 161, 398–413.
- Smith, M.J., Cloninger, C.R., Harms, M.P., Csernansky, J.G., 2008. Temperament and character as schizophrenia-related endophenotypes in non-psychotic siblings. *Schizophrenia Research* 104, 198–205.
- Someya, T., Sasaki, T., Hosoda, S., Takahashi, S., 1994. Reliability and validity of schizotypal personality questionnaire. *Archives of Psychiatric Diagnostic and Clinical Evaluations* 5, 98 (in Japanese).
- Sugishita, M., 2001. Japanese Wechsler Memory Scale-Revised. Nihonbunkakagakusha, Tokyo, in Japanese.
- Svrakic, D.M., Whitehead, C., Przybeck, T.R., Cloninger, C.R., 1993. Differential diagnosis of personality disorders by the seven-factor model of temperament and character. *Archives of General Psychiatry* 50, 991–999.
- Takahashi, H., Iwase, M., Canuet, L., Yasuda, Y., Ohi, K., Fukumoto, M., Iike, N., Nakahachi, T., Ikezawa, K., Azechi, M., Kurimoto, R., Ishii, R., Yoshida, T., Kazui, H., Hashimoto, R., Takeda, M., 2010. Relationship between prepulse inhibition of acoustic startle response and schizotypy in healthy Japanese subjects. *Psychophysiology* 47, 831–837.
- Takei, N., Sham, P., Callaghan, E., Glover, G., Murray, R., 1995. Early risk factors in schizophrenia: place and season of birth. *European Psychiatry* 10, 165–170.
- Tatsumi, M., Sasaki, T., Iwanami, A., Kosuga, A., Tanabe, Y., Kamijima, K., 2002. Season of birth in Japanese patients with schizophrenia. *Schizophrenia Research* 54, 213–218.
- Tochigi, M., Okazaki, Y., Kato, N., Sasaki, T., 2004. What causes seasonality of birth in schizophrenia? *Neuroscience Research* 48, 1–11.
- Torrey, E.F., Miller, J., Rawlings, R., Yolken, R.H., 1997. Seasonality of births in schizophrenia and bipolar disorder: a review of the literature. *Schizophrenia Research* 28, 1–38.
- Wang, J., Miyazato, H., Hokama, H., Hiramatsu, K., Kondo, T., 2004. Correlation between P50 suppression and psychometric schizotypy among non-clinical Japanese subjects. *International Journal of Psychophysiology* 52, 147–157.
- Wechsler, D., 1981. *Wechsler Adult Intelligence Scale, Revised*. Psychological Corporation, New York.
- Wechsler, D., 1987. *Wechsler Memory Scale Manual, Revised*. Psychological Corporation, San Antonio.



Contents lists available at ScienceDirect

Progress in Neuro-Psychopharmacology & Biological Psychiatry

journal homepage: www.elsevier.com/locate/pnp

A polymorphism of the *ABCA1* gene confers susceptibility to schizophrenia and related brain changes

Miho Ota^{a,*}, Takashi Fujii^{a,1}, Kiyotaka Nemoto^{b,c}, Masahiko Tatsumi^d, Yoshiya Moriguchi^c, Ryota Hashimoto^{a,e,f}, Noriko Sato^c, Nakao Iwata^{g,h}, Hiroshi Kunugi^a

^a Department of Mental Disorder Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, 4-1-1 Ogawa-Higashi, Kodaira, Tokyo 187-8502, Japan

^b Division of Psychiatry, Tsukuba University Hospital, 2-1-1 Amakubo, Tsukuba, Ibaraki 305-8576, Japan

^c Department of Radiology, National Center of Neurology and Psychiatry, 4-1-1, Ogawa-Higashi, Kodaira, Tokyo 187-8551, Japan

^d Yokohama Shinryo Clinic, Yokohama 221-0835, Japan

^e Molecular Research Center for Children's Mental Development, United Graduate School of Child Development, Osaka University, Kanazawa University and Hamamatsu University School of Medicine, D3, 2-2, Yamadaoka, Suita, Osaka, 565-0871, Japan

^f Department of Psychiatry, Osaka University Graduate School of Medicine, D3, 2-2, Yamadaoka, Suita, Osaka, 565-0871, Japan

^g Department of Psychiatry, School of Medicine, Fujita Health University, Toyoake, Aichi, Japan

^h Japan Science and Technology Agency, the Core Research for Evolutional Science and Technology, Kawaguchi, Japan

ARTICLE INFO

Article history:

Received 14 April 2011

Received in revised form 14 July 2011

Accepted 26 July 2011

Available online 3 August 2011

Keywords:

ATP-binding cassette transporter A1

Polymorphism

Schizophrenia

Voxel based morphometry

ABSTRACT

Objective: The ATP-binding cassette transporter A1 (*ABCA1*) mediates cellular cholesterol efflux through the transfer of cholesterol from the inner to the outer layer of the cell membrane and regulates extracellular cholesterol levels in the central nervous system. Several lines of evidence have indicated lipid and myelin abnormalities in schizophrenia.

Method: Initially, we examined the possible association of the polymorphisms of the *ABCA1* gene (*ABCA1*) with susceptibility to schizophrenia in 506 patients with schizophrenia (DSM-IV) and 941 controls. The observed association was then subject to a replication analysis in an independent sample of 511 patients and 539 controls. We further examined the possible effect of the risk allele on gray matter volume assessed with magnetic resonance imaging (MRI) in 86 patients with schizophrenia (49 males) and 139 healthy controls (47 males).

Results: In the initial association study, the 1587 K allele (rs2230808) was significantly more common in male patients with schizophrenia than in male controls. Although such a significant difference was not observed in the second sample alone, the increased frequency of the 1587 K allele in male patients remained to be significant in the combined male sample of 556 patients and 594 controls. Male schizophrenia patients carrying the 1587 K allele had a smaller amount of gray matter volume than those who did not carry the allele.

Conclusion: Our data suggest a male-specific association of the 1587 K allele of *ABCA1* with susceptibility to schizophrenia and smaller gray matter volume in schizophrenia.

© 2011 Elsevier Inc. All rights reserved.

Abbreviations: *ABCA1*, ATP-binding cassette transporter A1; ANCOVA, analysis of covariance; ANOVA, analysis of variance; CNS, central nervous system; DNA, deoxyribonucleic acid; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, 4th edition; FDR, false discovery rate; FWE, familywise error rate; GWAS, genome-wide association study; HDL, high-density lipoprotein; HWE, Hardy-Weinberg equilibrium; IL1 β , interleukin-1 β ; LDL, low-density lipoprotein; MINI, Mini-International Neuropsychiatric Interview; MRI, magnetic resonance imaging; mRNA, messenger ribonucleic acid; PCR, polymerase chain reaction; SNP, single nucleotide polymorphisms; SPM, Statistical Parametric Mapping; TE, echo time; TR, repetition time; VBM, voxel-based morphometry

* Corresponding author. Tel.: +81 42 341 2712; fax: +81 42 346 2094.

E-mail address: ota@ncnp.go.jp (M. Ota).

¹ Contributed equally to this work.

1. Introduction

The ATP-binding cassette transporter A1 (*ABCA1*) mediates cellular cholesterol efflux through transfer of cholesterol from the inner to the outer layer of the cell membrane, enabling the binding of cholesterol to apolipoproteins (Knight, 2004). It plays a critical role in the regulation of extracellular cholesterol levels in the central nervous system (CNS). Mice lacking the *ABCA1* gene (*ABCA1*) had significantly reduced cholesterol levels in the cerebrospinal fluid (Wahrle et al., 2004). Moreover, *ABCA1* polymorphisms are reported to be associated with serum cholesterol concentration. For instance, the 219K (rs2230806) allele was associated with high plasma levels of low-density lipoprotein (LDL) cholesterol (Katzov et al., 2004), and the 771M (rs2066718) and the 1587K (rs2230808) alleles were associated with low plasma levels of high-density lipoprotein (HDL) cholesterol (Clee et al., 2001; Frikke-Schmidt et al., 2004). Cholesterol is required for myelination (Saher

et al., 2005), dendrite differentiation (Goritz et al., 2005) and synaptogenesis (Mauch et al., 2001). Therefore ABCA1 expressed in neurons and glial cells plays an important role in the regulation of synaptic development (Karasinska et al., 2009). Estrogen administration is also known to increase ABCA1 messenger ribonucleic acid (mRNA) (Srivastava, 2002), and a sex difference in the activity of cholesterol transport has been observed (Catalano, 2008). Disturbances in CNS cholesterol homeostasis have been implicated in neurodegenerative diseases including Alzheimer's (Vance et al., 2005) and Huntington's diseases (Valenza et al., 2005). Previous studies have examined the association between polymorphisms of ABCA1, particularly the non-synonymous single nucleotide polymorphisms (SNPs) of rs2230806 (R219K), rs2066718 (V771M), and rs2230808 (R1587K) and risk for Alzheimer's disease. Some of these studies have shown a significant association (Katzov et al., 2004; Sundar et al., 2007; Shibata et al., 2006), although this association demonstrated a sex difference (Sundar et al., 2007). Several studies have demonstrated myelin abnormalities in schizophrenia (Thomas et al., 2001; Hakak et al., 2001; Garver et al., 2008; Tkachev et al., 2003; Huang and Chen, 2005), and the relationship between schizophrenia and ABCA1 was also noted (Chen et al., 2009). To date, sterol-regulatory-element binding protein-2 (SREBP-2), that regulates the ABCA1 (Wong et al., 2006), was suggested to be associated with schizophrenia (Le Hellard et al., 2010). Recent genetic studies also have revealed that the interleukin-1 β (IL1 β) gene or the IL1 gene complex is associated with schizophrenia (Xu and He, 2010), and it is also suggested that change in IL1 β levels in cerebrospinal fluid and serum may play a role in the pathophysiology of schizophrenia (Barak et al., 1995). IL-1 β has been shown to down-regulate ABCA1 (Chen et al., 2007). However, to our knowledge, no study has thus far focused on the association between ABCA1 polymorphisms and risk of schizophrenia. To our knowledge, no genome-wide association study (GWAS) has suggested that this chromosomal region contains a susceptibility locus for schizophrenia yet. However, some GWASs for bipolar disorder have reported this locus as a candidate region. Data from GWASs are also beginning to provide strong support for shared genetic risk across the disorders (Venken et al., 2005; Park et al., 2004; Liu et al., 2003; Badenhop et al., 2002). Interestingly, a recent study using data from GWASs strongly supported the hypothesis of shared genetic risk between schizophrenia and bipolar disorder (Moskvina et al., 2009). Thus we examined the possibility of association between the ABCA1 variants and schizophrenia.

Previous magnetic resonance imaging (MRI) studies in schizophrenia have shown gray matter volume reduction, particularly in the insula, anterior cingulate cortex, medial frontal cortex, and hippocampal area (Fornito et al., 2009; Glahn et al., 2008). Furthermore, studies have shown the effect of disease-associated genes on such structural abnormalities in the brain (Mata et al., 2009). Deviations in brain morphology potentially reflecting genetic risk have been ubiquitous in the literature, and quantitative measures of brain structure using various neuroimaging techniques have a long history as effective endophenotype (Honea et al., 2008). In this study, we examined whether genetic variations of ABCA1 are associated with the development of schizophrenia. We also investigated the potential influence of the disease-associated genotype of ABCA1 on the regional cerebral gray matter volume measured with MRI.

2. Methods

2.1. Subjects

2.1.1. Initial study (Tokyo sample)

Subjects were 506 patients with schizophrenia (278 males, mean age 44.3 ± 14.1 years), diagnosed according to the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) (American Psychiatric Association, 1994), and 941 healthy controls (334 males, 44.8 ± 16.3 years). All patients and controls were biologically unrelated

Japanese who resided in the same geographical area (the western part of Tokyo). Consensus diagnosis by at least two psychiatrists was made for each patient based on all the available information obtained from interviews and medical records. Healthy controls were interviewed for enrollment by research psychiatrists using the Japanese version of the Mini-International Neuropsychiatric Interview (MINI; Otsubo et al., 2005; Sheehan et al., 1998). Those who demonstrated no history of psychiatric illness or contact with psychiatric services were enrolled as controls in this study. Participants were excluded if they had a prior medical history of CNS disease or severe head injury. Among the subjects, 86 (49 males) schizophrenia patients and 139 healthy controls (47 males) underwent brain MRI.

2.1.2. Replication study (Tokai sample)

For the replication analysis, we used an independent Japanese sample comprising 511 cases (283 males, mean age 43.8 ± 14.9 years) and 539 controls (267 males, 36.3 ± 14.2 years). All subjects were unrelated, living in the Tokai area of the mainland of Japan, and self-identified as Japanese. Control subjects were members of the general public who had no personal history of mental disorders. This was ascertained in face-to-face interviews where subjects were asked if they had suffered an episode of depression, mania, or psychotic experiences or if they had received treatment for any psychiatric disorder. Patients were entered into the study if they 1) met DSM-IV criteria for schizophrenia; 2) were physically healthy and had normal routine laboratory tests; and 3) had no mood disorders, substance abuse, neurodevelopmental disorders, epilepsy, or known mental retardation. Consensus diagnoses were made by at least two experienced psychiatrists according to DSM-IV criteria on the basis of unstructured interviews with patients and families and review of medical records.

After description of the study, written informed consent was obtained from each subject. This study was approved by institutional ethics committees.

2.2. SNP selection and genotyping

Since genetic variations that result in an amino acid change are most likely to alter function, we searched for non-synonymous polymorphisms of ABCA1 in the NCBI dbSNP database (<http://www.ncbi.nlm.nih.gov/sites/entrez?db=snp>). We also searched the literature for polymorphisms of ABCA1 previously reported to be associated with CNS diseases. We found only four well-validated SNPs with a heterozygosity value of >0.10 in Asian populations: rs2230806 (R219K), rs2066718 (V771M), rs2066714 (I883M), and rs2230808 (R1587K). Venous blood was drawn from the subjects and genomic deoxyribonucleic acid (DNA) was extracted from whole blood according to the standard procedures. The four SNPs were genotyped using the TaqMan 5'-exonuclease allelic discrimination assay; the assay IDs were C_2741051_1_ for rs2230806, C_11720789_10 for rs2066718, C_2741083_1_ for rs2066714, and C_2741104_1_ for rs2230808 (Applied Biosystems, Foster City, CA). Thermal cycling conditions for polymerase chain reaction (PCR) were 1 cycle at 95°C for 10 min followed by 50 cycles of 92°C for 15 s and 60°C for 1 min. After amplification, the allele-specific fluorescence was measured on ABI PRISM 7900 Sequence Detection (Applied Biosystems). The genotypes were scored using the software SDS2.1. Failed reactions were called as 'undetermined' by this one and these data were not included in the analysis. Genotype data were read blind to the case-control status.

2.3. MRI data acquisition and processing

All MR studies were performed on a 1.5 Tesla Siemens Magnetom Vision plus system. A three-dimensional (3D) volumetric acquisition of a T1-weighted gradient echo sequence produced a gapless series of 144 sagittal sections using an MPRAGE sequence (echo time (TE)/repetition time (TR): 4.4/11.4 ms; flip angle: 15° ; acquisition

matrix: 256×256; 1NEX, field of view: 31.5 cm; slice thickness: 1.23 mm). The raw 3D T1-weighted volume data were transferred to a workstation, and structural images were analyzed using an optimized, voxel-based morphometry (VBM) technique. Data were analyzed using Statistical Parametric Mapping 5 (SPM5) software (Wellcome Department of Imaging Neuroscience, London, UK) running on MATLAB 7.0 (Math Works, Natick, MA). Images were processed using an optimized VBM script. The details of this process are described elsewhere (Li and Ji, 2005). First, each individual 3D-T1 image was normalized with the optimized VBM method. Normalized segmented images were modulated by multiplication with Jacobian determinants of the spatial normalization function to encode the deformation field for each subject as tissue density changes in normal space. Images were smoothed using an 8-mm full-width at half-maximum of an isotropic Gaussian kernel.

2.4. Statistical analysis

Deviations of genotype distributions from the Hardy–Weinberg equilibrium (HWE) were assessed with the χ^2 test for goodness of fit. First, genotype distributions were compared between patients and controls using the χ^2 test for independence. Since some animal studies showed the gender specific findings (Koldamova et al., 2005; Kuivenhoven et al., 2003), and estrogen has functional relevance to the ABCA1-mediated pathway (Srivastava, 2002) and a sex difference in the activity of cholesterol transport has been observed (Catalano et al., 2008), analysis for each sex was also performed. These tests were performed with SPSS software ver. 11 (SPSS Japan, Tokyo, Japan). For multiple analyses, we applied the spectral decomposition method of SNPSPD software (<http://gump.qimr.edu.au/general/daleN/SNPSPD/>) (Nyholt, 2004; Li and Ji, 2005), which considers marker linkage disequilibrium information and generates an experiment-wide significance threshold required to keep the type I error rate at 5%. As a result, the critical P value was corrected as 0.0128. Then, the observed association was subject to a replication analysis in an independent Tokai sample using the χ^2 test for independence.

Second, we then evaluated the differences in regional gray matter volume across the clusters sorted by the genotype distributions of the SNP that showed a statistically significant difference between the patients and healthy subjects. Statistical analyses were performed using Statistical Parametric Mapping 2 (SPM2) software (Wellcome Department of Imaging Neuroscience, London, UK). Since the regional cerebral gray matter volume is influenced by age (Good et al., 2001), we examined the differences in regional gray matter volume by the analysis of covariance (ANCOVA), controlling for age. Only associations that met the following criteria were deemed statistically significant for the first analysis: familywise error rate (FWE) < 0.05, and for the *post hoc* analyses: a voxel level of $p < 0.001$ (uncorrected) and a cluster level of $p < 0.05$ (uncorrected). We also evaluated the differences across the groups according to age using one-way analysis of variance (ANOVA) and the differences between two groups of schizophrenia patients categorized according to duration of illness and daily dose of antipsychotic drugs using a two-sample *t*-test.

3. Results

3.1. ABCA1 polymorphisms and susceptibility to schizophrenia

First, genotype and allele distributions of the 4 SNPs in the initial sample (Tokyo sample) are shown in Table 1. The genotype distribution for rs2230806 in the female control group deviated significantly from the HWE, thus was excluded from further analysis. In the total sample, the genotype or allele distribution did not differ significantly between the cases and controls for any SNP. However, when men and women were examined separately, a nominally significant difference in the genotype distribution for rs2230808 (R1587K) was observed in men

($p = 0.014$), but not in women ($p = 0.674$). Difference in allele frequency was observed at a trend level in men ($p = 0.055$), but not in women ($p = 0.440$). When the observed difference in the genotype distribution for rs2230808 was further analyzed based on the recessive and dominant models, there was a significant difference in the dominant model ($p = 0.006$; odds ratio (OR) 1.60, 95% confidential interval (CI): 1.14–2.24), but not in the recessive one ($p = 0.96$), in male subjects. There was no significant difference in genotype or allele distribution of the other 3SNPs even when subjects were stratified by sex.

Table 2 shows genotype and allele distributions for rs2230808 in the replication sample (Tokai sample). There was no significant difference in genotype or allele distribution between the patients and controls. When men and women were examined separately, there was no significant difference for either sex. We also analyzed based on the dominant model; however, no statistically significant differences in genotype distribution were found in total subjects or each sex. However, the initial and replication samples were combined, the frequency of male patients carrying the 1587K allele remained to be increased than male controls at nominally significant level (OR 1.30, 95% CI 1.02–1.65, $p = 0.032$).

3.2. ABCA1 polymorphism and MRI volumetry

Since carrying the 1587K allele was found to be significantly more common in male patients with schizophrenia than in male controls in the genetic association study, the subjects with MRI data were grouped into four groups for each sex based on the case–control status and whether the subject carried the 1587K allele or not. The demographic and clinical characteristics of the groups are presented in Table 3. For both men and women, the analyses showed no significant difference in duration of illness or daily dose of antipsychotics between the two genotype-based groups of patients with schizophrenia (men: duration of illness: $t(47) = -0.15$, $p = 0.88$, daily dose of drug: $t(47) = -1.58$, $p = 0.12$; female: duration of illness: $t(34) = -0.40$, $p = 0.69$, daily dose of drug: $t(34) = -0.20$, $p = 0.85$). Further, for both men and women, there was no significant difference in mean age across the healthy subjects and two schizophrenia groups (men: $df = 2$, $F = 1.54$, $p = 0.22$; women: $df = 2$, $F = 1.16$, $p = 0.32$).

Initially, we evaluated the difference in gray matter volume between the two genotype-based healthy groups for each sex using ANCOVA, controlling for age. There were no significant differences related to genotype for either sex, respectively. We therefore combined the healthy groups with and without the 1587K allele for each sex in the following analyses. When the group effect was assessed using ANCOVA with F-test (FWE < 0.05), we found statistically significant volume differences in thalami, medial temporal regions, and nearly all the circumferential cortical regions in males (Fig. 1A). Male patients with schizophrenia carrying the 1587K allele showed significant small gray matter volume in the bilateral occipital regions and posterior cingulate cortices compared with those who did not carry the 1587K allele (Fig. 1B). Male patients with schizophrenia who did not carry the 1587K allele showed significant small volume only in bilateral orbitofrontal, insulae, and left parahippocampus, compared with all male controls (Fig. 1C). However, the male schizophrenia patients carrying the 1587K allele showed smaller volume across almost the whole gray matter, than all male controls (Fig. 1D). When we re-analyzed these *post hoc* statistics using rigorous criteria (false discovery rate (FDR) $p < 0.05$, cluster level of $p < 0.05$), results indicated with Fig. 1C and D showed almost the same as the previous ones, the statistics using the relatively small sample size indicated with the Fig. 1B showed no statistically significant difference between the schizophrenic groups.

In women, in contrast, there were no significant differences in gray matter volume between schizophrenia patients with and without the 1587K allele or between controls with and without the allele (data not

Table 1
Genotype and allelic distributions of the ABCA1 SNPs in patients with schizophrenia and controls.

db SNP ID and aminoacid change	Position*	Inter-SNP distance (bp)	Gender	Group	N	Genotype distribution (frequency)			χ^2	P	Allele count (frequency)		χ^2	P	HWE of Controls (df = 1)			
						R/R	R/K	K/K			R	K						
rs2230806 Arg219Lys	107620867 exon 7	(-)	All	Schizophrenia	497	119 (0.24)	241 (0.48)	137 (0.28)	2.77	0.250	479	(0.48)	515	(0.52)	0.01	0.897	$\chi^2 = 3.73$ P = 0.053	
				Controls	932	204 (0.22)	495 (0.53)	233 (0.25)			903	(0.48)	961	(0.52)				
				M	Schizophrenia	274	63 (0.23)	137 (0.50)	74 (0.27)	0.47	0.789	263	(0.48)	285	(0.52)	0.45	0.503	$\chi^2 = 0.05$ P = 0.827
					Controls	330	71 (0.22)	162 (0.49)	97 (0.29)			304	(0.46)	356	(0.54)			
				F	Schizophrenia	223	56 (0.25)	104 (0.47)	63 (0.28)			216	(0.48)	230	(0.52)			$\chi^2 = 6.81$ P = 0.009
					Controls	602	133 (0.22)	333 (0.55)	136 (0.23)			599	(0.50)	605	(0.50)			
						V/V	V/M	M/M			V	M						
rs2066718 Val771Met	107589255 exon 16	31,612	All	Schizophrenia	494	438 (0.89)	54 (0.11)	2 (0.00)	1.09	0.580	930	(0.94)	58	(0.06)	0.99	0.319	$\chi^2 = 0.04$ P = 0.847	
				Controls	936	812 (0.87)	120 (0.13)	4 (0.00)			1744	(0.93)	128	(0.07)				
				M	Schizophrenia	273	242 (0.89)	29 (0.11)	2 (0.01)	1.70	0.428	513	(0.94)	33	(0.06)	0.50	0.480	$\chi^2 = 0.30$ P = 0.582
					Controls	333	287 (0.86)	45 (0.14)	1 (0.00)			619	(0.93)	47	(0.07)			
				F	Schizophrenia	221	196 (0.89)	25 (0.11)	0 (0.00)	1.32	0.518	417	(0.94)	25	(0.06)	0.60	0.437	$\chi^2 = 0.03$ P = 0.856
					Controls	603	525 (0.87)	75 (0.12)	3 (0.00)			1125	(0.93)	81	(0.07)			
						I/I	I/M	M/M			I	M						
rs2066714 Ile883Met	107586753 exon 18	34,114	All	Schizophrenia	487	208 (0.43)	212 (0.44)	67 (0.14)	3.86	0.145	628	(0.64)	346	(0.36)	1.75	0.186	$\chi^2 = 0.91$ P = 0.339	
				Controls	917	345 (0.38)	446 (0.49)	126 (0.14)			1136	(0.62)	698	(0.38)				
				M	Schizophrenia	266	115 (0.43)	116 (0.44)	35 (0.13)	3.23	0.199	346	(0.65)	186	(0.35)	0.87	0.335	$\chi^2 = 2.40$ P = 0.122
					Controls	330	122 (0.37)	168 (0.51)	40 (0.12)			412	(0.62)	248	(0.38)			
				F	Schizophrenia	221	93 (0.42)	96 (0.43)	32 (0.14)	1.23	0.542	282	(0.64)	160	(0.36)	0.62	0.430	$\chi^2 = 0.002$ P = 0.966
					Controls	587	223 (0.38)	278 (0.47)	86 (0.15)			724	(0.62)	450	(0.38)			
						R/R	R/K	K/K			R	K						
rs2230808 Arg1587Lys	107562804 exon 35	58,063	All	Schizophrenia	491	174 (0.35)	252 (0.51)	65 (0.13)	4.05	0.132	600	(0.61)	382	(0.39)	0.63	0.427	$\chi^2 = 0.50$ P = 0.478	
				Controls	923	367 (0.40)	422 (0.46)	134 (0.15)			1156	(0.63)	690	(0.37)				
				M	Schizophrenia	273	87 (0.32)	148 (0.54)	38 (0.14)	8.51	0.014	322	(0.59)	224	(0.41)	3.68	0.055	$\chi^2 = 1.17$ P = 0.278
					Controls	327	140 (0.43)	141 (0.43)	46 (0.14)			421	(0.64)	233	(0.36)			
				F	Schizophrenia	218	87 (0.40)	104 (0.48)	27 (0.12)	0.79	0.674	278	(0.64)	158	(0.36)	0.60	0.440	$\chi^2 = 0.01$ P = 0.945
					Controls	596	227 (0.38)	281 (0.47)	88 (0.15)			735	(0.62)	457	(0.38)			

HWE; Hardy-Weinberg equilibrium.

* Chromosome position was determined from the dbSNP database.

Table 2
Genotype and allelic distributions of rs2230808 in independent replication sample.

db SNP ID and aminoacid change	Gender	Group	N	Genotype distribution (frequency)			χ^2	P	Allele count (frequency)		χ^2	P	HWE of controls (df=1)		
				R/R	R/K	K/K			R	K					
rs2230808 Arg1587Lys	All	Schizophrenia	539	211 (0.39)	252 (0.47)	76 (0.14)	0.25	0.88	676	(0.63)	404	(0.37)	0.03	0.85	$\chi^2 = 0.49$ P = 0.48
		Controls	511	201 (0.39)	233 (0.46)	77 (0.15)			635	(0.62)	387	(0.38)			
	M	Schizophrenia	283	109 (0.39)	133 (0.47)	41 (0.14)	0.15	0.93	351	(0.62)	215	(0.38)	0.14	0.71	$\chi^2 = 0.01$ P = 0.92
		Controls	267	106 (0.40)	125 (0.47)	36 (0.13)			337	(0.63)	197	(0.37)			
	F	Schizophrenia	256	102 (0.40)	119 (0.46)	35 (0.14)	0.97	0.62	323	(0.63)	189	(0.37)	0.43	0.51	$\chi^2 = 1.17$ P = 0.28
		Controls	244	95 (0.39)	108 (0.44)	41 (0.17)			298	(0.61)	190	(0.39)			

HWE; Hardy–Weinberg equilibrium.

shown). We evaluated the difference between the all controls and all cases using ANCOVA. The female schizophrenia patients showed smaller gray matter volume in the bilateral insulae, anterior cingulate cortex, and orbitofrontal cortex, than all female controls (Fig. 1E).

We also we evaluated the difference in gray matter volume between the schizophrenic groups with and without the 1587K allele for each sex using ANCOVA, controlling for age, duration of illness, educational period, and medication. There were no statistically significant differences between the groups for each sex, however, male patients with schizophrenia carrying the 1587K allele showed small gray matter volume in the left occipital region and bilateral posterior cingulate cortices, almost the same as Figure (B), compared with those who did not carry the 1587K allele at nominal trend level (F) ($P < 0.01$ uncorrected). There were no differences between the female schizophrenic patients with or without the 1587K allele using loose criteria ($P < 0.01$ uncorrected, data not shown).

4. Discussion

We found that the 1587K allele of *ABCA1* was significantly more common in male patients with schizophrenia than in male controls. However, such a difference was not observed in women. Furthermore, our results showed that male schizophrenic patients who carried the 1587K allele have smaller gray matter volume than in those who did not, but this difference did not extend to women. To our knowledge, this is the first study that reports the possible association of *ABCA1* with susceptibility to schizophrenia and related brain abnormalities.

4.1. *ABCA1* polymorphisms and susceptibility to schizophrenia

The 1587K allele was reported to increase cerebrospinal fluid tau level and brain amyloid beta load (Katzov et al., 2004). It was also associated with low plasma levels of apolipoprotein A1 (Tregouet et al., 2004) and HDL-cholesterol (Clee et al., 2001; Frikke-Schmidt et al., 2004), suggesting functional differences between the R1587 and 1587K alleles, which may explain our results.

The present study showed gender-specific association between R1587K (rs2230808) and schizophrenia in our population. Serum from men displays an enhanced free cholesterol efflux capacity via the *ABCA1* transporter pathway compared with that from perimenopausal women (Catalano et al., 2008). Estradiol was known to modulate a wide range of functions of the brain. From the onset of menopause, declining levels of estradiol can cause cognitive disturbances and changes in behavior that can be counterbalanced by hormone replacement. Studies in mice have suggested that the atheroprotective effects of estrogen may occur partly via the *ABCA1*-mediated pathway (Srivastava, 2002). Another study found that *ABCA1* was up-regulated by estradiol (Sárvári et al., 2010). Taking these previous findings into consideration, the observed sex difference in our study may be explained, at least in part, by the fact that estrogen is involved in the regulation of *ABCA1* activity. The role of CNS cholesterol in synaptic function and neurodegenerative disorders has recently been appreciated, but the mechanisms regulating its transport and homeostasis are only partially understood. Therefore, further studies that focused on the sex difference should be needed to reveal the function of the *ABCA1*.

In the initial study, the 1587K allele (rs2230808) was significantly more common in male patients with schizophrenia than in male controls. Although such a significant difference was not observed in the second sample alone, the increased frequency of the 1587K allele in male patients remained to be significant in the combined male sample. Though there was the association of *ABCA1* with susceptibility to schizophrenia, it is suggested that this relationship may be fairly weak.

4.2. *ABCA1* polymorphism and MRI volumetry

Our results showed that male schizophrenia patients carrying the 1587K allele showed smaller gray matter volume than those who did not carry the allele. Schizophrenia has been associated with volume reductions in the limbic, paralimbic, frontal, and temporal cortical regions (Glahn et al., 2008; Ellison-Wright et al., 2008; Shenton et al., 2001; Wright et al., 2000), although some previous studies did not detect disturbances in such regions (Kanaan et al., 2005; Kubicki et al.,

Table 3
Characteristics of the subjects who underwent MRI.

		Genotype distribution of rs2230808	N	Age	Duration of illness	Drug dose (chlorpromazine equivalent)
Men	Control	R/R	21	39.8 ± 12.4 (20–71)	21.0 ± 16.9	770.0 ± 636.0
		K carrier	26	38.9 ± 11.9 (25–69)		
		All	47	39.3 ± 12.0 (20–71)		
Women	Schizophrenia	R/R	16	44.7 ± 16.7 (22–76)	21.7 ± 12.9	1183.6 ± 945.7
		K carrier	33	43.7 ± 13.0 (27–72)		
		All	49	44.2 ± 15.8 (22–74)		
Women	Control	R/R	39	48.2 ± 13.5 (25–74)	17.2 ± 13.2	691.6 ± 566.3
		K carrier	53	39.9 ± 11.6 (22–71)		
		All	92	43.4 ± 13.0 (22–74)		
	Schizophrenia	R/R	16	47.5 ± 12.3 (22–67)	19.0 ± 13.2	731.2 ± 623.9
		K carrier	21	46.3 ± 15.0 (23–75)		
		All	37	46.9 ± 14.1 (23–75)		




Fig. 1. Group effect was assessed using analysis of covariance (ANCOVA) (SPM2). Age was used as a nuisance variable. (A); There were statistically significant volume differences among the 3 groups of men, i.e., the male schizophrenia patients with and without the 1587K allele and the entire male control group. (B); Male schizophrenia patients carrying the 1587K allele showed gray matter volume reduction in the bilateral occipital regions and posterior cingulate cortices compared with those who did not carry this allele. (C); There were volume decreases in the bilateral insulae and orbitofrontal regions, and the left parahippocampal region in male patients with schizophrenia without the 1587K allele compared with all male controls. (D); Male patients with schizophrenia carrying the 1587K allele showed volume reduction in almost all the gray matter areas, compared with all male controls. (E); When all female schizophrenia patients were analyzed collectively, they showed gray matter volume reduction in the bilateral insulae, anterior cingulate cortex, and orbitofrontal cortex, compared with all female controls. (F); We also evaluated the difference in gray matter volume between the schizophrenic groups with and without the 1587K allele for each sex using ANCOVA, controlling for age, duration of illness, educational period, and medication. Male patients with schizophrenia carrying the 1587K allele showed small gray matter volume in the left occipital region and bilateral posterior cingulate cortices, compared with those who did not carry the 1587K allele controlling for age, duration of illness, educational period, and medication, at nominal trend level ($P < 0.01$ uncorrected).

2007). Two broad theories have been proposed to describe the pattern of cerebral changes: the global and macro-circuit theories (Buchsbaum et al., 2006). According to the global theory, white matter reductions occur uniformly throughout the brain, possibly as a result of genetic abnormalities in the protein pathways controlling myelination (Konrad and Winterer, 2008). The alternative macro-circuit theory proposes that specific white matter tracts are disrupted in schizophrenia either as a cause or a consequence of a disorder in the gray matter regions they connect (Konrad and Winterer, 2008). The present results may accord with the global theory by showing smaller volume in almost the entire gray matter in male schizophrenia patients carrying the 1587K allele of *ABCA1*, because *ABCA1* was regarded as the key regulator of brain cholesterol homeostasis and associated with structure and function in neurons such as myelination (Karasinska et al., 2009). Both male and female schizophrenia patients who did not carry the 1587K allele showed smaller volume in the medial temporal region, insulae, and anterior cingulate cortex, which have been referred to as predominantly impaired brain regions in schizophrenia,

than control subjects (Glahn et al., 2008; Ellison-Wright et al., 2008). On the other hand, the male patients with schizophrenia carrying the 1587K allele showed the smaller volume in the occipital regions and posterior cingulate cortices, where it is known to remain unchanged from illness, than male patients not carrying 1587K allele. Intricate analysis controlling for age, duration of illness, educational period, and medication, male patients carrying 1587K allele showed the smaller volume in occipital and posterior cingulate cortices compared with male patients not carrying 1587K allele, only at the trend level, but these tendencies could not be detected in females even at the trend level. From these points, we suggest a male-specific association of the 1587K allele of *ABCA1* with susceptibility to schizophrenia and smaller gray matter volume in schizophrenia. In this study, we evaluated only a gray matter volume change, and no consideration was paid to the white matter. Further work with the diffusion tensor imaging data will be necessary to confirm our results.

Schizophrenia is a multifactorial disorder caused by a complex interaction of genetic and environmental factors (Bassett et al., 2001).

In this study, we found no significant difference in gray matter volume related to the R1587K polymorphism in healthy subjects. This may be accounted for by the possibility that *ABCA1* polymorphism interacts with other risk factors for schizophrenia and that these collectively influence brain vulnerability.

References

- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Press; 1994.
- Badenhop RF, Moses MJ, Scimone A, Mitchell PB, Ewen-White KR, Rosso A, et al. A genome screen of 13 bipolar affective disorder pedigrees provides evidence for susceptibility loci on chromosomes 3 as well as chromosomes 9, 13 and 19. *Mol Psychiatry* 2002;7:851–9.
- Barak V, Barak Y, Levine J, Nisman B, Roisman I. Changes in interleukin-1 beta and soluble interleukin-2 receptor levels in CSF and serum of schizophrenic patients. *J Basic Clin Physiol Pharmacol* 1995;6:61–9.
- Bassett AS, Chow EW, O'Neill S, Brzustowicz LM. Genetic insights into the neurodevelopmental hypothesis of schizophrenia. *Schizophr Bull* 2001;27:417–30.
- Buchsbaum MS, Schoenkecht P, Torosjan Y, Newmark R, Chu KW, Mitelman S, et al. Diffusion tensor imaging of frontal lobe white matter tracts in schizophrenia. *Ann Gen Psychiatry* 2006;5:19.
- Catalano G, Duchene E, Le Julia Z, Goff W, Bruckert E, Chapman MJ, et al. Cellular SR-BI and ABCA1-mediated cholesterol efflux are gender-specific in healthy subjects. *J Lipid Res* 2008;49:635–43.
- Chen M, Li W, Wang N, Zhu Y, Wang X. ROS and NF-kappaB but not LXR mediate IL-1beta signaling for the downregulation of ATP-binding cassette transporter A1. *Am J Physiol Cell Physiol* 2007;292:1493–501.
- Chen X, Sun C, Chen Q, O'Neill FA, Walsh D, Fanous AH, et al. Apoptotic engulfment pathway and schizophrenia. *PLoS One* 2009;4:e6875.
- Clee SM, Zwinderman AH, Engert JC, Zwarts KY, Molhuizen HO, Roomp K, et al. Common genetic variation in ABCA1 is associated with altered lipoprotein levels and a modified risk for coronary artery disease. *Circulation* 2001;103:1198–205.
- Ellison-Wright I, Glahn DC, Laird AR, Thelen SM, Bullmore E. The Anatomy of first-episode and chronic schizophrenia: an anatomical likelihood estimation meta-analysis. *Am J Psychiatry* 2008;165:1015–23.
- Fornito A, Yücel M, Patti J, Wood SJ, Pantelis C. Mapping grey matter reductions in schizophrenia: an anatomical likelihood estimation analysis of voxel-based morphometry studies. *Schizophr Res* 2009;108:104–13.
- Frikke-Schmidt R, Nordestgaard BG, Jensen GB, Tybjaerg-Hansen A. Genetic variation in ABC transporter A1 contributes to HDL cholesterol in the general population. *J Clin Invest* 2004;114:1343–53.
- Garver DL, Holcomb JA, Christensen JD. Compromised myelin integrity during psychosis with repair during remission in drug-responding schizophrenia. *Int J Neuropsychopharmacol* 2008;11:49–61.
- Glahn DC, Laird AR, Ellison-Wright I, Thelen SM, Robinson JL, Lancaster JL, et al. Meta-analysis of gray matter anomalies in schizophrenia: application of anatomical likelihood estimation and network analysis. *Biol Psychiatry* 2008;64:774–81.
- Good CD, Johnsrude I, Ashburner J, Henson RNA, Friston KJ, Frackowiak RSJ. Cerebral asymmetry and the effect of sex and handedness on brain structure: a voxel-based morphometric analysis of 465 normal adult human brains. *Neuroimage* 2001;14:685–700.
- Goritz C, Mauch DH, Pfrieger FW. Multiple mechanisms mediate cholesterol-induced synaptogenesis in a CNS neuron. *Mol Cell Neurosci* 2005;29:190–201.
- Hakak Y, Walker JR, Li C, Wong WH, Davis KL, Buxbaum JD, et al. Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. *Proc Natl Acad Sci USA* 2001;98:4746–51.
- Honea RA, Meyer-Lindenberg A, Hobbs KB, Pezawas L, Mattay VS, Egan MF, et al. Is gray matter volume an intermediate phenotype for schizophrenia? A voxel-based morphometry study of patients with schizophrenia and their healthy siblings. *Biol Psychiatry* 2008;63:465–74.
- Huang TL, Chen JF. Serum lipid profiles and schizophrenia: effects of conventional or atypical antipsychotic drugs in Taiwan. *Schizophr Res* 2005;80:55–9.
- Kanaan RA, Kim JS, Kaufmann WE, Pearson GD, Barker CJ, McGuire PK. Diffusion tensor imaging in schizophrenia. *Biol Psychiatry* 2005;58:921–9.
- Karasinska JM, Rinninger F, Lütjohann D, Ruddle P, Franciosi S, Kruit JK, et al. Specific loss of brain ABCA1 increases brain cholesterol uptake and influences neuronal structure and function. *J Neurosci* 2009;29:3579–89.
- Katzov H, Chalmers K, Palmgren J, Andreasen N, Johansson B, Cairns NJ, et al. Genetic variants of ABCA1 modify Alzheimer disease risk and quantitative traits related to beta-amyloid metabolism. *Hum Mutat* 2004;23:358–67.
- Knight BL. ATP-binding cassette transporter A1: regulation of cholesterol efflux. *Biochem Soc Trans* 2004;32:124–7.
- Koldamova R, Staufenbiel M, Lefterov I. Lack of ABCA1 considerably decreases brain APOE level and increases amyloid deposition in APP23 mice. *J Biol Chem* 2005;280:43224–35.
- Konrad A, Winterer G. Disturbed structural connectivity in schizophrenia primary factor in pathology or epiphenomenon? *Schizophr Bull* 2008;34:72–92.
- Kubicki M, McCarley R, Westin CF, Park HJ, Maier S, Kikinis R, et al. A review of diffusion tensor imaging studies in schizophrenia. *J Psychiatr Res* 2007;41:15–30.
- Kuivenhoven JA, Hovingh GK, van Tol A, Jauhiainen M, Ehnholm C, Fruchart JC, et al. Heterozygosity for ABCA1 gene mutations: effects on enzymes, apolipoproteins and lipoprotein particle size. *Atherosclerosis* 2003;171:311–9.
- Le Hellard S, Mühleisen TW, Djurovic S, Fernø J, Ouriaghi Z, Mattheisen M, et al. Polymorphisms in SREBF1 and SREBF2, two antipsychotic-activated transcription factors controlling cellular lipogenesis, are associated with schizophrenia in German and Scandinavian samples. *Mol Psychiatry* 2010;15:463–72.
- Li J, Ji L. Adjusting multiple testing in multilocus analyses using the eigenvalues of a correlation matrix. *Heredity* 2005;95:221–7.
- Liu J, Juo SH, Dewan A, Grunn A, Tong X, Brito M, et al. Evidence for a putative bipolar disorder locus on 2p13-16 and other potential loci on 4q31, 7q34, 8q13, 9q31, 10q21-24, 13q32, 14q21 and 17q11-12. *Mol Psychiatry* 2003;8:333–42.
- Mata I, Perez-Iglesias R, Roiz-Santiañez R, Tordesillas-Gutierrez D, Gonzalez-Mandly A, Vazquez-Barquero JL, et al. A neuregulin 1 variant is associated with increased lateral ventricle volume in patients with first-episode schizophrenia. *Biol Psychiatry* 2009;65:535–40.
- Mauch DH, Nagler K, Schumacher S, Goritz C, Müller EC, Otto A, et al. CNS synaptogenesis promoted by glia-derived cholesterol. *Science* 2001;294:1354–7.
- Moskvina V, Craddock N, Holmans P, Nikolov I, Pahwa JS, Green E. Wellcome Trust Case Control Consortium, Owen MJ, O'Donovan MC. Gene-wide analyses of genome-wide association data sets: evidence for multiple common risk alleles for schizophrenia and bipolar disorder and for overlap in genetic risk. *Mol Psychiatry* 2009;14:252–60.
- Nyholt DR. A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. *Am J Hum Genet* 2004;74:765–9.
- Otsubo T, Tanaka K, Koda R, Shinoda J, Sano N, Tanaka S, et al. Reliability and validity of Japanese version of the Mini-International Neuropsychiatric Interview. *Psychiatry Clin Neurosci* 2005;59:517–26.
- Park N, Juo SH, Cheng R, Liu J, Loth JE, Lilliston B, et al. Linkage analysis of psychosis in bipolar pedigrees suggests novel putative loci for bipolar disorder and shared susceptibility with schizophrenia. *Mol Psychiatry* 2004;9:1091–9.
- Saher G, Brugger B, Lappe-Siefke C, Mobius W, Tozawa R, Wehr MC, et al. High cholesterol level is essential for myelin membrane growth. *Nat Neurosci* 2005;8:468–75.
- Sárvári M, Kalló I, Hrabovszky E, Solymosi N, Tóth K, Likó I, et al. Estradiol replacement alters expression of genes related to neurotransmission and immune surveillance in the frontal cortex of middle-aged, ovariectomized rats. *Endocrinology* 2010;151:3847–62.
- Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. *J Clin Psychiatry* 1998;59(suppl. 20):22–57.
- Shenton ME, Dickey CC, Frumin M, McCarley RW. A review of MRI findings in schizophrenia. *Schizophr Res* 2001;49:1–52.
- Shibata N, Kawarai T, Lee JH, Lee HS, Shibata E, Sato C, et al. Association studies of cholesterol metabolism genes (CH25H, ABCA1 and CH24H) in Alzheimer's disease. *Neurosci Lett* 2006;391:142–6.
- Srivastava RA. Estrogen-induced regulation of the ATP-binding cassette transporter A1 (ABCA1) in mice: a possible mechanism of atheroprotection by estrogen. *Mol Cell Biochem* 2002;240:67–73.
- Sundar PD, Feingold E, Minster RL, DeKosky ST, Kambh MI. Gender-specific association of ATP-binding cassette transporter 1 (ABCA1) polymorphisms with the risk of late-onset Alzheimer's disease. *Neurobiol Aging* 2007;28:856–62.
- Thomas EA, Dean B, Pavey G, Sutcliffe JG. Increased CNS levels of apolipoprotein D in schizophrenic and bipolar subjects: implications for the pathophysiology of psychiatric disorders. *Proc Natl Acad Sci USA* 2001;98:4066–71.
- Tkachev D, Mimmack ML, Ryan MM, Wayland M, Freeman T, Jones PB, et al. Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. *Lancet* 2003;362:798–805.
- Tregouet DA, Ricard S, Nicaud V, Arnould I, Soubigou S, Rosier M, et al. In-depth haplotype analysis of ABCA1 gene polymorphisms in relation to plasma ApoA1 levels and myocardial infarction. *Arterioscler Thromb Vasc Biol* 2004;24:775–81.
- Valenza M, Rigamonti D, Goffredo D, Zuccato C, Fenu S, Jamot L, et al. Dysfunction of the cholesterol biosynthetic pathway in Huntington's disease. *J Neurosci* 2005;25:9932–9.
- Vance JE, Hayashi H, Karten B. Cholesterol homeostasis in neurons and glial cells. *Semin Cell Dev Biol* 2005;16:193–212.
- Venken T, Claes S, Sluijs S, Paterson AD, van Duijn C, Adolfsson R, et al. Genomewide scan for affective disorder susceptibility Loci in families of a northern Swedish isolated population. *Am J Hum Genet* 2005;76:237–48.
- Wahrle SE, Jiang H, Parsadanian M, Legleiter J, Han X, Fryer JD, et al. ABCA1 is required for normal central nervous system ApoE levels and for lipidation of astrocyte-secreted apoE. *J Biol Chem* 2004;279:40987–93.
- Wong J, Quinn CM, Brown AJ. SREBP-2 positively regulates transcription of the cholesterol efflux gene, ABCA1, by generating oxysterol ligands for LXR. *Biochem J* 2006;400:485–91.
- Wright IC, Rabe-Hesketh S, Woodruff PWR, David AS, Murray RM, Bullmore ET. Meta-analysis of regional brain volumes in schizophrenia. *Am J Psychiatry* 2000;157:16–25.
- Xu M, He L. Convergent evidence shows a positive association of interleukin-1 gene complex locus with susceptibility to schizophrenia in the Caucasian population. *Schizophr Res* 2010;120:131–42.

RESEARCH

Open Access

Possible association between *Interleukin-1beta* gene and schizophrenia in a Japanese population

Daimei Sasayama^{1,2*}, Hiroaki Hori^{1,3}, Toshiya Teraishi¹, Kotaro Hattori¹, Miho Ota¹, Yoshimi Iijima⁴, Masahiko Tatsumi⁵, Teruhiko Higuchi⁶, Naoji Amano² and Hiroshi Kunugi^{1,3}

Abstract

Background: Several lines of evidence have implicated the pro-inflammatory cytokine interleukin-1beta (IL-1 β) in the etiology of schizophrenia. Although a number of genetic association studies have been reported, very few have systematically examined gene-wide tagging polymorphisms.

Methods: A total of 533 patients with schizophrenia (302 males: mean age \pm standard deviation 43.4 \pm 13.0 years; 233 females; mean age 44.8 \pm 15.3 years) and 1136 healthy controls (388 males: mean age 44.6 \pm 17.3 years; 748 females; 46.3 \pm 15.6 years) were recruited for this study. All subjects were biologically unrelated Japanese individuals. Five tagging polymorphisms of *IL-1 β* gene (rs2853550, rs1143634, rs1143633, rs1143630, rs16944) were examined for association with schizophrenia.

Results: Significant difference in allele distribution was found between patients with schizophrenia and controls for rs1143633 ($P = 0.0089$). When the analysis was performed separately in each gender, significant difference between patients and controls in allele distribution of rs1143633 was observed in females ($P = 0.0073$). A trend towards association was also found between rs16944 and female patients with schizophrenia ($P = 0.032$).

Conclusions: The present study shows the first evidence that the *IL-1 β* gene polymorphism rs1143633 is associated with schizophrenia susceptibility in a Japanese population. The results suggest the possibility that the influence of *IL-1 β* gene variations on susceptibility to schizophrenia may be greater in females than in males. Findings of the present study provide further support for the role of IL-1 β in the etiology of schizophrenia.

Background

Several lines of evidence suggest that pro-inflammatory cytokine interleukin-1beta (IL-1 β) is implicated in the etiology and pathophysiology of schizophrenia. Although studies investigating peripheral levels of IL-1 β in schizophrenic patients have reported inconsistent results [1-6], a study examining the cerebrospinal fluid has shown a marked elevation of IL-1 β in patients with first-episode schizophrenia compared to healthy controls [7]. Kowalski et al [8] reported that the release of IL-1 β by peripheral monocytes was increased before treatment and then normalized by antipsychotic medication in patients with schizophrenia. Recently, Liu et al. [9] showed that IL-1 β in the peripheral blood mononuclear cells was overexpressed not

only in schizophrenia patients but also in their siblings, suggesting the involvement of the hereditary factors. Furthermore, previous findings suggested that IL-1 β may be involved in the possible link between prenatal exposure to infection and schizophrenia [10,11].

The *IL-1 β* gene is located in a region on 2q14. This region has consistently shown positive linkage findings in schizophrenia. Many studies have reported this region among their largest results [12,13]. Furthermore, Lewis et al [14] have shown in their meta-analysis of 20 genome scans that 2p12-q22.1 was associated with a genomewide significant P value. Linkage of this region with schizophrenia in an Asian population has also been reported [15].

A number of genetic association studies have suggested that genetic variation of the *IL-1 β* gene might confer susceptibility to schizophrenia. Three studies in Caucasian populations reported a significant association of schizophrenia with an *IL-1 β* gene polymorphism

* Correspondence: sasayama@shinshu-u.ac.jp

¹Department of Mental Disorder Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Kodaira, Tokyo, 187-8502, Japan

Full list of author information is available at the end of the article